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Abstract
CHROMOSOMAL PROTEINS IN ACTIVATION OF TRANSCRIPTION
by
Benjamin Michael Shykind
Submitted to the department of Biology in partial fulfillment for the degree
Doctor of Philosophy
Transcription by RNA polymerase II requires multiple auxiliary factors for
accurate initiation. The positive modulation of this reaction requires a further set of
factors, collectively called coactivators, that are not required for the unregulated or basal
initiation of transcription. Coactivators can be divided into two groups: TATA binding
protein (TBP) associated, and soluble. Both groups appear to be required for activated
levels of transcription. The exact mechanism by which activators, in collaboration with
coactivators, enhance the basal reaction remains unknown. This thesis presents
experiments designed to advance the understanding of this fundamentally important
biological process.
Using an in vitro transcription system unresponsive to activators as a functional
assay, an activity was identified that potentiated activation. This coactivator was purified
to homogeneity by standard biochemical means and identified by amino acid sequencing
as the non-histone chromosomal protein HMG-2. Subsequently, the highly related HMG-
1 protein, and the 80 amino acid HMG box B were demonstrated to by coactivators.
These proteins have DNA binding and bending activity and have been included in a
group of protein known as "architectural factors" for their ability to impart structure to
DNA. Coactivation with HMG-proteins was shown to require the factor TFIIA and the
TFIID-TFIIA stage of initiation was the first step in transcription altered in the activation
process. The inability to detect a quantitative change at this critical step led to the
proposal that a qualitative change takes place during this stage of activation that
facilitates transcription.
Another chromosomal protein that coactivates stimulation, DNA topoisomerase I,
was examined in vitro. This coactivator also functioned at the TFIID-TFIIA stage of
activation as determined by order-of-addition transcription. The activation event was
associated by a dramatic enhancement in the formation of the TFIID-TFIIA complex as
demonstrated by electrophoretic mobility shift assay (EMSA). This enhancement of
complex formation required the concomitant participation of TFIID, TFIIA, activator and
topoisomerase I, exactly analogous to the conditions required for maximal activation.
DNase I footprinting confirmed the EMSA analysis. The effect of enhanced complex
formation on the activation process is likely both quantitative and qualitative.
Thesis Supervisor: Phillip A. Sharp
Title: Professor of Biology
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Chapter I
Introduction
Introduction
Overview
The regulation of the production of mRNA in the cell mirrors the complexity of
all of development, as the determination of cell fate depends primarily on the correct
expression of the genes transcribed by RNA polymerase II. Therefore, the elucidation of
the process that delivers polymerase II to correct loci is of great importance to the
understanding of biological processes. Since the first demonstration of accurate initiation
of RNA polymerase II (pol II) transcription in a cell extract seventeen years ago (Weil et
al., 1979), the understanding of the initiation of transcription in vitro has advanced to the
point where the earliest steps in the process have now been described by x-ray
crystallography to roughly 2.5 A resolution (Kim et al., 1993a; Kim et al., 1993b;
Nikolov et al., 1995). Despite this progress, the critical aspects of regulation of the pol 11
machinery, are still being uncovered.
This thesis describes experiments to advance the understanding of the mechanism
of activation of pol II transcription. The determination of the factors involved, and their
function in the process, has been undertaken. In the first part of this introductory chapter,
the components of the process that effects accurate initiation of pol II transcription will be
described. These factors, many of which have now had their cDNAs isolated, fulfill
specific duties in the transcription cycle. Each step in this cycle is carried out by protein-
DNA and protein-protein interactions with enough specificity to fix the site of the start of
transcription with high fidelity. The cell exerts a great deal of control on this process and
there is evidence of positive and negative modulation of each step in the reaction.
The DNA segment that directs the accurate initiation of transcription by pol II is
the promoter, a region of DNA immediately upstream of the gene, encompassing
approximately fifty nucleotides from around +10 to -40. This region typically contains a
TATA element at -30, and often an initiator (Inr) element centered on +1 (Smale and
Baltimore, 1989). While this region is capable of directing accurate initiation, more
distal cis-acting elements, typically upstream, are required for the dramatic induction of
gene expression observed in vivo (Banerji et al., 1981). These distal elements function as
binding sites for sequence specific factors (activators) that mediate the activation or
enhancement of the process. Transcriptional activation will be reviewed in the second
part of this chapter.
The enzyme that polymerizes ribonucleotides into mRNA using DNA as a
template, the RNA polymerase II, cannot accurately initiate transcription from the
promoter on its own. Additional protein factors are required. These proteins, termed the
general transcription factors (GTFs), recognize the promoter, recruit and help position the
polymerase, enable it to enter the coding region where mRNA is transcribed, and finally,
promote the successful full length elongation of nascent RNA chain. Although able to
carry out accurate initiation of transcription (referred to as the "basal" reaction), this
ensemble of almost fifty polypeptides cannot on its own be positively modulated by
upstream elements. Additional factors are required. These factors have variously been
termed coactivators, adaptors, or mediators. This thesis is primarily concerned with these
factors and their mechanisms of action. The second part of the introduction will describe
current understanding about them.
Knowledge about the regulation of transcription has moved forward by the
dissection of the basal reaction. We now turn to the description of the factors that effect
basal, unregulated transcription and their roles in forming the structure that positions and
launches RNA polymerase II.
The Basal Reaction
The recruitment of RNA polymerase II to the promoter is accomplished through
the step-wise assembly of a protein complex. This assembly can be broken down into
functional stages as described in Figure 1. The factors responsible for many of these
steps have been identified and their roles are now being clarified. As derepression can be
considered a positive modulation of the reaction, the first step we will consider is the
initial and stable recognition of the promoter by protein factors or "nucleation."
Figure 1. Schematic view of the pol II transcription cycle
Nucleation
Upon successful early fractionation of the mammalian cell extracts that supported
accurate initiation (Matsui et al., 1980; Samuels et al., 1982), those crude fractions that
reconstituted transcription were examined by DNA interference and template
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commitment assays to determine roughly their stage of participation in the reaction. Two
second column fractions required for transcription, DB and AB (TFIID and TFIIA
respectively), were found to form a complex on the adenovirus major late promoter which
was resistant to inhibition by addition of excess DNA (Fire et al., 1984). Similar results
were obtained on the conalbumin promoter (Davison et al., 1983). This stable complex
was proposed to be the first step in promoter recognition and to give long term activity to
the promoter, although there was no direct evidence of promoter binding. This evidence
came from DNase I footprinting of the Drosophila and mammalian factors (Parker and
Topol, 1984; Sawadogo and Roeder, 1985) The requirement for TFIIA in the formation
of the committed complex on the promoter was subsequently brought into question by
studies that demonstrated the ability of the TFIID fraction alone to stably commit
(Sawadogo and Roeder, 1985; Van Dyke et al., 1989). However, the purity of TFIID
remained a critical issue in the interpretation of these results. The complexes formed on
the major late promoter during initiation were convincingly demonstrated by gel shift
assay using the yeast TFIID. In this study, TFIIA was shown to alter the TFIID footprint,
extending it upstream (Buratowski et al., 1989).
The mammalian TFIID activity proved extremely difficult to purify. However, in
S. cerevisiae an activity that complemented an in vitro transcription reaction lacking
TFIID was identified (Buratowski et al., 1988). Yeast TFIID supported accurate
initiation in a mammalian in vitro system and footprinted over the TATA box. This
activity was estimated to be 23-27kD in mass, much smaller than the estimate of almost
1000kD for mammalian TFIID. Additionally, it differed from its mammalian counterpart
by the production of a smaller footprint over the TATA region. Yeast TFIID purification
was amenable to conventional chromatography which led to the isolation of its cDNA
clone (Cavallini et al., 1989; Eisenmann et al., 1989; Hahn et al., 1989; Horikoshi et al.,
1989; Schmidt et al., 1989). The corresponding Drosophila and human counterparts to
the yeast TFIID were cloned using P.C.R. with degenerate primers based on the yeast
sequence (Hoey et al., 1990; Peterson et al., 1990). Again, the cloned TFIIDs did not
behave like the purified TFIIDs: the recombinant protein was unable to support regulated
transcription by upstream activators, was smaller (43kD for the human) than the
endogenous activity, and had a smaller footprint. The physical and functional differences
between cloned and recombinantly expressed, and endogenous TFIIDs led to the proposal
that the endogenous TFIID was a multisubunit complex (Hoey et al., 1990; Pugh and
Tjian, 1990). Definitive proof for this proposal came when the endogenous Drosophila
TFIID was immunoprecipitated and found to be complexed with several associated
factors. The fly TFIID activity was composed of the 45kD TATA binding protein (TBP)
and TBP associated factors (TAFs) of 150, 110, 80, 60, 40, and 32kD, which were also
shown to potentiate the response to activation (Dynlacht et al., 1991). Subsequently, a
TAF-TBP complex from human TFIID was also identified (Tanese et al., 1991; Zhou et
al., 1992). The properties of endogenous TFIID were recapitulated by combinations of
TBP and TAFs. The extended footprint seen with endogenous TFIID was found in
Drosophila to be mediated by TAF 150 (Verrijzer et al., 1994). Recently, TAFs have
been demonstrated to promote TFIID binding to different core promoter elements
(Verrijzer et al., 1995). The coactivating properties of TAFs will be discussed in the
second part of this introduction. The discovery of TAFs in higher metazoans prompted a
reexamination of yeast TBP. This led to the demonstration that yeast TBP could be
immunoprecipitated in the company of a number of other polypeptides (Poon and Weil,
1993; Poon et al., 1995). This yeast TBP complex has been shown to be required for
stimulated transcription in vitro (Reese et al., 1994).
The role of TFIIA in nucleation, or formation of the first stable promoter-protein
complex, has been confirmed by recent experiments. Mammalian TFIIA was purified to
homogeneity and found to be made up of polypeptides of 35, 19, and 12kD; the larger
two subunits were found to be derived from the same gene (DeJong and Roeder, 1993;
Ma et al., 1993). The cDNA of the smaller subunit was also cloned, making it possible to
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polymerase. TFIIB is believed to determine this start-site position; yeast TFIIB was first
isolated as a start-site alteration suppressor (Pinto et al., 1992). The role of TFIIB in
start-site selection was convincingly demonstrated in experiments where an S. pombe
start-site was utilized in an S. cerevisiae in vitro reaction only when both S. pombe
polymerase and TFIIB were substituted into the system (Li et al., 1994). Recently the x-
ray structure of the TBP-TFIIB-DNA complex was reported. This structure shows TFIIB
binding underneath TBP and making contacts with the DNA backbone and the c-
terminal stirrup of TBP (Nikolov et al., 1995).
RNA polymerase II is composed of ten subunits and has a molecular weight of
about 500kD. A prominent feature of the largest subunit is the repetitive C-terminal
domain (CTD) which is a substrate for phosphorylation. The phosphorylation state of the
CTD is thought to play a role in transcription regulation. The Ilo form of pol II is heavily
phosphorylated while the IIa form in unphosphorylated. Pol IIA is found in the
assembled initiation complex while Pol IIO is the form found in elongating complexes
(Payne et al., 1989). However, the CTD is not required for transcription from the adeno
major late promoter. Interestingly, there may be core promoter specificities for the
requirement of the CTD (Akoulitchev et al., 1995)
Clearance
At the end of assembly, the promoter is bound by TFIID, TFIIA, TFIIB, TFIIF,
and Pol II, with the polymerase correctly positioned. With the addition of NTPs, this
complex can send off an elongation complex, depending on the superhelical state and
type of the promoter (Parvin and Sharp, 1993). In the absence of negative superhelical
tension, the assembled complex requires TFIIE, TFIIH, and ATP hydrolysis for the
elongation complex to clear the immediate promoter region (Goodrich and Tjian, 1994).
TFIIE is a heterodimer with subunits of 34 and 56kD (Ohkuma et al., 1990; Inostroza et
al., 1991). TFIIH is composed of at least eight polypeptides and is associated with two
helicase activities, an ATPase, and a kinase activity that has been shown to phosphorylate
the CTD of polymerase. TFIIH also shares subunits with the nucleotide excision repair
mechanism (Drapkin et al., 1994). The exact mechanism of promoter clearance is not yet
understood. However, it is fair to say that TFIIE-TFIIH-ATP driven clearance is
obviated by the energy stored in negative superhelical tension, suggesting that the
helicase activity in TFIIH may function in moving the elongation complex away from the
immediate promoter region. Additionally, the phosphorylation state of the polymerase
may play a part in the conversion of the initiating polymerase to the elongating form
(reviewed by (Buratowski, 1994).
Reinitiation
The study of multiple-round transcription has yet to come under the intense
scrutiny given initiation. It could be proposed that the study of reinitiation, rather than is
initiation, is more germane to activation. This is due to the fact that increased initiations
per time, or activation, must by definition involve mechanisms of reinitiation more often
than strategies of initiation. Control of initiation may be more related to regulation by
derepression. However, several interesting features that distinguish initiation from
reinitiation have come to light in the past few years. The fate of the general factors has
been traced by Zawel and Reinberg following the departure of the polymerase from the
promoter (Zawel et al., 1995). As was expected, TFIID remained bound to its site. Upon
the formation of the first phosphodiester bonds, TFIIB was released from the complex.
TFIIF and TFIIE were released somewhere within the first ten nucleotides. Interestingly,
TFIIH was the last GTF released; this occurred somewhere between +30 and +68.
Important to the process of reinitiation, TFIIB once released from the initiation complex,
promptly reassociated with the promoter bound TFIID. Thus presumably signaling the
start of the next assembly process. A factor that boosted reinitiation was identified by
polymerase collision assay that was subsequently identified as the elongation factor
TFIIS (Szentirmay and Sawadogo, 1991). Interestingly, first round transcription was
found to be less dependent on TFIIS than were reinitiates, highlighting a difference in
factor requirement between the two processes (Szentirmay and Sawadogo, 1993). It is
possible that multiple round transcription will have an increased need for topoisomerase I
(see below) over single round transcription as the torsional tension generated by
elongation should increase with each polymerase loaded (Wang, 1992).
Elongation
Polymerase II is not only unable to accurately initiate transcription on its own, but
likely is unable to complete elongation or full-length transcription without help. Several
factors have been shown to have elongation or anti-pausing activity including TFIIF
(Flores et al., 1989; Price et al., 1989), TFIIS (Reinberg and Roeder, 1987; Bengal et al.,
1991) and the elongins (Aso et al., 1995). Additionally, topoisomerase I has been shown
to promote elongation (Egyhazi and Durban, 1987). The elongating polymerase may
traverse the gene on its own, and recruit elongation factors when it gets stuck; TFIIF has
been shown to be associated with stalled polymerases (Zawel et al., 1995). As an
example of the pitfalls of biochemical identification of factors, the reported elongation
factor TFIIJ (Cortes et al., 1992) turned out to be an RNAse inhibitor (D. Reinberg,
personal communication). This spurious identification occurred when rRNAsin was
omitted from in vitro transcription reactions.
Derepression
The dissection of the transcription reaction has primarily been carried out on DNA
templates devoid of chromosomal proteins. However, the physiological state of the gene
is a nucleoprotein complex called chromatin. The packaging of DNA into nucleosomes
can have repressive effects on transcription (reviewed in Paranjape et al., 1994). This
repression can be circumvented by prebinding of initiation factors, such as TFIID, to the
template, prior to chromatinization (Workman and Roeder, 1987). Alleviation of
chromatin repression is also believed to occur through the active reconfiguration of
nucleosome structure. This active derepression has been reported in yeast to be mediated
by a multicomponent complex of SWI and SNF gene products (Hirschhorn et al., 1992,
and references therein). Such nucleosome remodeling activities have recently been found
in human and Drosophila extracts (Kwon et al., 1995; Tsukiyama et al., 1995). This
active reconfiguration is believed to make promoters accessible to transcription factor
binding. Thus the first step in transcription initiation may well be the active derepression
of the chromatinized promoter region.
Derepression may take place at other points in the pathway as well. Partially
formed complexes can become blocked by specific inhibitors, preventing subsequent
assembly. A mammalian factor called Drl has been shown to bind to TBP and prevent
assembly of the TBP-TFIIA complex by formation of a competitive TBP-Drl complex
on the promoter. The TBP-TFIIB complex is similarly unable to form in the presence of
Dri unless TFIIA is present in sufficient quantity. Another factor, ADI, which was
isolated from yeast prevents the binding of TBP to the promoter (Auble and Hahn, 1993).
ADI requires ATP for its inhibitory function and like Drl is blocked by preassociation of
TBP with TFIIA. The abundant chromosomal enzyme topoisomerase I has been shown
to inhibit transcription in a manner similar to Drl (Merino et al., 1993).
Holocomplexes
The primacy of the stepwise model of assembly of the initiation complex has
recently been challenged by the finding that polymerase can be isolated in a large
complex containing many of the GTFs (Koleske et al., 1992; Thompson et al., 1993;
Koleske and Young, 1994; Ossipow et al., 1995). Thus some of the GTFs may arrive at
the promoter preassembled, bypassing some of the steps of assembly.
We can now draw a schematic summary of the transcription cycle and map it onto
an idealized control region (Figure 2). The locations of factor function on the promoter
are correlated with their stage of action in the transcription cycle.
Figure 2. Transcription cycle mapped onto an idealized gene
Activators, which bind to specific sites, typically, but not necessarily, upstream of the
basal machine, positively modulate this process. The remainder of this introduction will
focus on the factor requirements for activation and the differences between the basal and
activated initiation complexes.
Activation
Overview
There are now a large number of well characterized sequence-specific DNA
binding proteins that stimulate transcription from binding sites distant from the region of
initiation. The mechanism by which these activator proteins increase the rate of initiation
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is the subject of intense research. As summarized in the first part of this introduction, the
factors that bring the polymerase to the start site have been defined. However, the basal
reaction, the target of activation, has been found to be deficient in its ability to be
positively modulated by activators in vitro. The missing activities that bridge the
functional and perhaps literal gap between the activator and the basal machinery are
known as coactivators. These activities can be subdivided into soluble or non-TBP
associated, and TBP-bound or TAFs. Many of the defined soluble coactivators have been
shown to act generally, by mediating activation equally well from all activators. There
are also reports of activator specific coactivators. The TAFs, as an ensemble, are general
coactivators but individually have activator specificities. Activator proteins are bipartite,
containing separable DNA binding and activation domains (Hope and Struhl, 1986).
Activation domains fall into classes based on the amino acid moieties they contain.
Many groups have demonstrated interactions between members of the GTFs and
activation domains. Such interactions have been proposed to mediate some aspect of
activation.
Using functional assays a number of groups have attempted to define the step of
initiation potentiated by activators. Despite various lines of evidence implicating
different stages of initiation as being altered by activators, no conclusive picture has
emerged of the mechanism of activation. It may be that there is no single mechanism and
that activator alters many stages of initiation. The assorted interactions between
activation domains and GTFs may all define relevant intermediates of the process. It
could be that the templates used by many labs to study the reaction may be too far
removed from the actual, physiologically significant, chromatinized promoter. Thus a
definitive activating event may be detected by standard biochemical means, once the
process is studied in nucleosome packaged templates.
Coactivators
TBP associated factors
As soon as yeast TFIID was isolated, and found to be unable to support activation
in an in vitro reaction, it became clear that either mammalian TFIID, which supported
activation, was a quite different protein, or was associated with enabling factors. A
number of unsuccessful attempts were made to force the putative enabling factors to
function with yeast TBP. When human TBP was cloned and also found to fail to support
stimulation in vitro, the case for the existence of associated factors (as opposed to post-
translational modifications) that enabled activation was strengthened (Pugh and Tjian,
1990). Subsequently immunoprecipitation of Drosophila TFIID revealed that TBP was
adorned with several stably bound proteins. Crude isolation of these associated proteins
revealed them to possess coactivating activity (Dynlacht et al., 1991). Human TFIID was
found to be complexed with TAF coactivators as well (Tanese et al., 1991). The large
number of TAFs were proposed to potentially accommodate the diversity of activation
domains. Several TAF-activator interactions have been demonstrated including: TAF
110 with Spl, TAFs 40 and 60 with VP 16, TAFs 40 and 60 with p53, and TAF 40 with
EBNA-2 (Goodrich et al., 1993; Hoey et al., 1993; Tjian and Maniatis, 1994; Thut et al.,
1995). The functional significance of many of these activator-TAF interactions have
been confirmed by mutant studies where loss of activation and loss of binding were
correlated. The TAFs isolated from yeast have recently been shown to possess
coactivator function in vitro (Reese et al., 1994).
Soluble coactivators
USA
A set of GTFs of sufficient purity, and a third column TFIID fraction (containing
TAFs) that responded very weakly to various activators, led to the discovery of a family
of coactivators not tightly associated with TBP (Meisterernst et al., 1991b). This activity,
termed USA for "upstream factor stimulatory activity," was further separated into
positive and negative cofactors (PCs and NCs). Of the PCs 1-4, the best characterized are
PC-4 and PC-3. PC-4 was purified to homogeneity and its cDNA isolated (Ge and
Roeder, 1994; Kretzschmar et al., 1994). PC-4 was shown to bind to activation domains
and to the TBP-TFIIA complex, thus having the potential to bridge the activator and the
basal complex. PC4 had non-specific DNA binding activity and its coactivating activity
was negatively modulated by phosphorylation (Kretzschmar et al., 1994).
DNA Topoisomerase I/PC-3
In the course of the in vitro analyses of factors required for activation, Merino et
al. purified an activity from HeLa cells that potentiated stimulation by Gal4-AH called
Dr2. This activity additionally repressed the basal reaction in the absence of TFIIA. Dr2
was purified to homogeneity and identified as topoisomerase I (Merino et al., 1993) .
Subsequently, Roeder's group also identified topoisomerase I as the coactivator PC3
(Kretzschmar et al., 1993). Topoisomerase I was shown to coimmunoprecipitate with the
TFIID complex and to interact with TBP as shown by Far Western. Interestingly, Merino
et al. demonstrated a promoter specificity for repression which suggested the requirement
for a TATA element for repression by topoisomerase I. The transcriptional activity of
topoisomerase I in these in vitro reactions was convincingly demonstrated to be
independent of its relaxing activity, as a point mutant of topoisomerase I, unable to relax
supercoils, retained its ability to affect transcription. Further, wild type topoisomerase I
from yeast, vaccinia virus, and E. coli had no transcriptional properties in this
mammalian transcription system.
The helical structure of DNA had suggested to some, a priori, that a "swivel"
would be required in transcription such that polymerases could avoid rotating about the
axis of the coding region DNA during elongation (Wang, 1985, and references therein).
Thus topoisomerase I has been implicated in transcription elongation, a post-initiation
step. Substantiating this proposal, a number of studies have localized topoisomerase I to
actively transcribed regions of the genome. Nucleosomes from actively transcribed genes
were found to contain topoisomerase I (Weisbrod, 1982). Additionally, heat shock loci
on Drosophila polytene chromosomes stained with anti-topoisomerase I antibodies after
induction, but not before (Fleischmann et al., 1984). Further, UV crosslinking trapped
topoisomerase I on active genes in Drosophila (Gilmour et al., 1986). Finally,
topoisomerase I-coding region DNA covalent intermediates were demonstrated by the
inhibitor camptothecin, to be tightly associated with induction of the tyrosine
aminotransferase gene (Stewart and Schutz, 1987), and the c-fos gene (Stewart et al.,
1990). In addition to the localization of topoisomerase I to the coding regions of genes,
there is evidence of a topoisomerase I site in a promoter region of a gene (Stewart and
Schutz, 1987). Thus convincing evidence exists demonstrating the ability of
topoisomerase I to coactivate transcription in vitro. Meanwhile, in vivo efforts have
focused on demonstrating a role for the enzyme in elongation. It is possible that
topoisomerase I joins the initiation complex during activation and is then loaded into the
elongation complex, but no data exists for this presumption.
HMG proteins
Those cellular proteins that eluted from isolated nuclei at 350mM NaC1, were
soluble in 2% trichloroacetic acid, and migrated rapidly in electrophoresis were given the
operational name high mobility group or HMG proteins (reviewed in Bustin et al., 1990;
Grosschedl et al., 1994). There are three types of HMG proteins, unrelated by sequence
homology. They do share some interesting properties such as the ability to bind to DNA
and nucleosomes, and the possession of highly charged regions. All three groups, HMG-
1/2, HMG-14/17 and HMG-I(Y), have now been identified as transcriptional
coactivators.
HMG-1 /2
The HMG-1/2 proteins have been described as modulators of pol II transcription
in a variety of crude systems (Tremethick and Molloy, 1988; Watt and Molloy, 1988;
Singh and Dixon, 1990). Recently they have also been demonstrated to coactivate
stimulation by a variety of activators in a defined reaction (Shykind et al., 1995).
HMG14 and 17
This HMG family has been implicated in transcription by its association with
active chromatin (Weisbrod, 1982). HMG-17 was shown to be a chromatin specific
coactivator with Gal4-VP16 (Paranjape et al., 1995). Its coactivating activity functioned
on nucleosomal but not naked DNA. The highly related HMG-14 has been reported to
promote elongation on transcription from SV40 mini-chromosomes (Ding et al., 1994).
HMG I(Y)
Induction of the human interferon- 3 gene by virus was demonstrated to require
both the activator NF-icB and HMG-I(Y) in vivo (Thanos and Maniatis, 1992). HMG-
I(Y) was shown to bind to the promoter along with the activator such that mutations
which abolished HMG-I(Y) binding dramatically reduced in vivo activation levels.
HMG-I(Y) was further shown to enhance the in vitro binding of NF-KCB homo and
heterodimers possibly by altering the structure of the promoter region DNA.
ADAs
In vitro transcriptions with the potent activator Gal4-VPl6 in yeast extracts led to
the observation that over-addition of activator diminished activated levels of transcription
before basal levels were altered (Berger et al., 1990). Further, over-expression of Gal4-
VPl6 was found to be toxic in yeast, dependent on a functional activation domain. This
led to a genetic screen that identified suppressors of the activator toxicity including
ADA2, ADA3, ADA5 and GCN5 (Berger et al., 1992, and reviewed in Guarente, 1995).
The products of ADA genes have properties of coactivators.
Holopolymerase/Mediator
The heptapeptide repeats of the CTD of RNA polymerase II play an important
regulatory role in yeast. Truncations of these repeats leads to various conditional growth
phenotypes. Suppressors were isolated that reverted the growth phenotypes of CTD
truncations (Nonet and Young, 1989). These suppressors, called SRBs "for suppressors
of RNA polymerase B," were shown to form a massive complex with the polymerase
containing in addition TFIIB, TFIIH, and TFIIF which was called the holopolymerase.
Activation in vitro with this holoenzyme required the addition of only TBP, TFIIE and
the activator (Koleske and Young, 1994). A similar polymerase complex termed the
mediator was isolated from yeast and reported to contain SRBs, TFIIF, SUG1, and
GALl1 (Kim et al., 1994). A mutation in the GALl 1 component that generated an
interaction domain with the GAL4 dimerization domain was shown to be sufficient for
activation, dependent on GAL4 (Barberis et al., 1995). SUG1 had been identified in a
screen for suppressors of a GAL4 activation domain mutation (Swaffield et al., 1995).
Activator-specific coactivators
A number of soluble factors have been shown to potentiate stimulation
specifically from a single activator, in contrast to the general coactivators described
above. These specific coactivators include CBP, which binds to the cAMP-regulated
enhancer binding protein (CREB) when CREB is activated by protein kinase A
phosphorylation (Kwok et al., 1994). Interestingly, CBP can bind to the GTF TFIIB.
Further, CBP shares homology with the yeast coactivator ADA-2. The adenovirus E1A
protein, which mediates both repression and activation of gene expression, binds to a
cellular factor called p300. This large protein has been implicated as a coactivator by the
ability of a mutant form to restore activity to an SV40 enhancer silenced by E1A (Eckner
et al., 1994). Recently, p300 was shown to be a functional homologue of CBP in vivo
(Lundblad et al., 1995). Another candidate for an activator restricted coactivator is the
factor Bob-1, which was isolated by virtue of its ability to interact with the lymphoid-
restricted activator Oct-2 (Gstaiger et al., 1995). Bob-1 boosts activation by Oct-2 and to
a lesser extent Oct-1, in vivo. The potent Herpes virus activator VPl6 functions through
an octamer-like motif via association with Oct-1 mediated by a factor called C 1 (Kristie
and Sharp, 1990). The assembly of this large complex likely controls the activity of this
element.
Thus the participation of sequence-specific activating proteins in the stimulation
of transcription requires yet another level of protein-protein interaction. This level is the
domain of coactivators, which may be working upon the basal factors as intermediates of
the activator, or enabling direct and functional interaction between activator and the basal
machine. Coactivators may be classified as activator-specific or activator-general. The
TAFs as an ensemble can be considered activator-general although certain TAFs may
mediate activation from specific classes of activators. It is likely that the TAFs and the
soluble coactivators must both be present to support stimulation although it is possible
that certain promoter contexts or activators may break this rule. The next section of this
introduction will examine mechanism of activation, using the paradigm of assembly of
the initiation complex described earlier in this introduction.
Mechanisms of Activation
The schematic view of assembly on the promoter can now be modified to
highlight the stages of initiation proposed to be altered by activators (Figure 3).
1. (Workman et al., 1991; Croston et al., 1992)
2. (Sawadogo and Roeder, 1985; Abmayr et al., 1988; Horikoshi et al., 1988;
Stringer et al., 1990; Wang et al., 1992; White et al., 1992; Lieberman and Berk, 1994;
Kaiser et al., 1995; Sauer et al., 1995; Shykind et al., 1995)
3. (Lin and Green, 1991; Choy and Green, 1993; Kim and Roeder, 1994; Chi et al., 1995)
4. (Xiao et al., 1994)
5. (Yankulov et al., 1994)
Figure 3. Points of activation described in the literature.
From the number of references cited for nucleation (step 2), it is clear that much attention
has been focused on the stage where TFIID and TFIIA form a stable complex. In
addition, compelling data exists for the derepression of transcription by activators, and
elegant and convincing experiments have demonstrated the significance of the TFIIB
binding step as well. In this last section I will review the reported stages and possible
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mechanisms of activator function, basing the analysis on the steps of transcription
schematically described in Figures 2 and 3.
Activator derepression
A paradigm for gene regulation has been proposed wherein the gene can exist in
three states: an inactive or ground state, a derepressed state, and an activated state
(Grunstein et al., 1992; Paranjape et al., 1994). The inactive state is mediated by
nucleosome position, the condensation of chromatin, or by non-histone chromosomal
protein repressors. Derepression brings the gene from the ground state to a basal state,
and true activation occurs on the derepressed gene. The role of activators then is to first
derepress the promoter, allowing free access for the GTFs, and second to aid in the
assembly of those GTFs such that initiations per time are increased. In vitro experiments
with synthetic Gal4 based activators have shown that the acidic activation domain can
function more efficiently in assembled chromatin by dramatically increasing the induced
to uninduced ratio, as the basal level of transcription drops away due to chromatin
mediated repression (Workman et al., 1991). This effect, which depended on the
presence of the activation domain, not simply the DNA binding domain, led the authors
to conclude that the activator was functioning by helping the initiation complex compete
for binding with nucleosomes. An investigation using histone H1 and H1 containing
chromatin showed similarly that activator could prevent repression of transcription
(Croston et al., 1992). These authors showed that local nucleosome structure in the
promoter was disrupted by the activator DNA binding domain alone, but that this was not
sufficient for derepression.
Nucleation
The stage of initiation complex assembly where GTF (TFIID +/- TFIIA) first
recognizes the cis-regulatory elements of the promoter has received a great deal of
scrutiny in studies of activation. Studying the effect of the upstream regulatory factor
USF (MLTF) on adeno major late promoter transcription, a link was made between
activator and TFIID binding (Sawadogo and Roeder, 1985). In this study, a crude TFIID
fraction was shown to stabilize USF binding and thus an interaction between the two
factors was proposed. DNase I footprinting showed that the TFIID fraction made contact
with the TATA box and also with almost forty base pairs of downstream DNA. This
extended footprint was not dependent on the activator, but subtle changes in the footprint
upon binding of both factors led the authors to propose that the interaction between USF
and TFIID could result in a conformational change in TFIID that may be accompanied by
extensive wrapping of the DNA around the complex and facilitation of the subsequent
steps in initiation. The TFIID binding step was also implicated in the mechanism of
pseudorabies immediate early protein activation (Abmayr et al., 1988). In this study,
prebinding of a crude (second column) TFIID fraction to the promoter obviated the need
for activator to reach stimulated levels of transcription. This suggested to the authors that
facilitated binding of TFIID was the mechanism of activation. Using the adenovirus E4
promoter, a synthetic Gal4 binding domain based activator was demonstrated to have
dramatic effects on the downstream footprint of a crude TFIID fraction (Horikoshi et al.,
1988). In this study, the extended TFIID footprint observed upon TFIID binding to the
major late promoter alone, was induced on the E4 promoter by functional activator
protein. Thus a direct interaction between the activator and the TFIID was proposed by
the authors. The mammalian activator ATF gave a similar alteration of TFIID footprint
on the E4 promoter (Horikoshi et al., 1988b). Using oligonucleotide competition to
remove activator from the promoter, this study concluded that once established, the
altered TFIID footprint was maintained in the absence of activator. In an accompanying
report, ATF function was examined in transcription assays with oligonucleotide
competition (Hai et al., 1988). ATF binding site oligo inhibited transcription if added at
time zero with all the partially purified GTFs and ATF. However, the reaction was
refractory to oligo addition if the template was preincubated with TFIID, TFIIB, and pol
II along with ATF. The ATF-TFIID complex, which showed an altered footprint, was
not an oligo-refractory complex, indicating that the ATF altered TFIID complex was not
the activated complex. However, this study did emphasize the early action of ATF in
activation. These early forays into the mechanism of activation used only partially
purified factors at a time when the entire complement of GTFs had not yet been
elucidated. Further, the existence of coactivators was then unknown. Thus factor-factor
cross contamination diminishes the resolution of some of these results but not the
inference of activator function early in the process. Further suggestion of an early stage
of activator function resulted from the demonstration that the potent activation domain of
VP16, when immobilized, could retain TFIID activity from nuclear HeLa extract
(Stringer et al., 1990). Further, this domain could bind to recombinant yeast TBP. A
control for the biological significance of this result was the correlation of poor TFIID
binding and low activity of a transcriptionally compromised point mutant VP 16 (Ingles et
al., 1991).
Using potassium permanganate footprinting to assess start-site melting (open
complex formation) TFIID-TFIIA complex formation was identified as the rate-limiting
step facilitated by activator (Wang et al., 1992). Interestingly, this activator increase in
start-site melting would not occur if TFIID alone, or TFIID plus TFIIA were preincubated
with the template, even if activator was added subsequently. This work was carried out
with partially purified factors. The TFIID used here likely contained topoisomerase I (see
chapter III). Sarkosyl (a detergent which prevents initiation complex formation but does
not inhibit elongation) and anti-Gal4-VP16 antibodies were used to probe activator
function. This produced a result suggesting (through extremely circuitous logic) that the
activator acted just after template commitment by TFIID and TFIIA (White et al., 1992).
The use of reagents purified to apparent homogeneity, and a direct physical assay
(gel-shift), suggested that the role of the activator was the recruitment of TFIID,
dependent on TFIIA and the TAFs (Lieberman and Berk, 1994). The TFIID used in this
study was immunoaffinity purified an estimated 15,000 fold (holoTFIID) and could be
detected binding to radiolabeled probe in agarose gel EMSA (Zhou et al., 1992). In this
study, the viral activator Zta was shown to increase the rate and extent of formation of the
TFIID-TFIIA complex, and to stabilize the complex. DNase I footprinting revealed
alterations in the TFIID footprint in the presence of Zta similar to those seen with ATF
and cruder TFIID. This activator dependent loading was not completely correlated with
activation, as stimulation in an in vitro transcription assay further required the coactivator
fraction USA. However, an oligonucleotide challenge transcription assay demonstrated
that the Zta-TFIID-TFIIA-promoter complex was a rapidly forming, oligonucleotide
resistant entity. The authors concluded that Zta increased the formation of an
intermediate in the initiation pathway and induced a conformational change in the TFIID-
TFIIA complex that may alter the binding of subsequent GTFs. The TFIID-TFIIA stage
was also identified as a first step in activation in a highly purified transcription system
using the coactivator PC4 (Kaiser et al., 1995). PC4 and the activator Gal4-AH were
found to stimulate formation of the TFIID-TFIIA complex at limiting levels of TFIID,
and to have modest effects on later GTF assembly as well. This work used a restriction
enzyme cleavage of the activator site to temporally dissect activation. This showed the
requirement for the continued presence of activation, after TFIID-TFIIA formation, for
full activation in the system.
Recently recombinant Drosophila TFIID subcomplexes were assembled which
showed the TAF requirements of activational synergy brought about by the two activators
Bicoid and Hunchback (Sauer et al., 1995). In this study TAFs 60, 110, and 250 were
required to be present in the TBP complex in order to support synergy. DNase I
footprinting demonstrated that the activators recruited the TBP-TAF complex to the
promoter, suggesting that a critical feature of activation is TFIID recruitment via TAF-
activator interaction. It is interesting to note that TFIIA was not required for this
recruitment. It is unclear whether the Drosophila in vitro transcription system used here
was free of soluble coactivators.
The recognition of the promoter by TFIID and TFIIA generates a stable complex.
Extensive contacts are made with the DNA by a combination of TBP and TAF
interactions which may be facilitated, and are certainly altered, by TFIIA. The TBP
component of TFIID was the first GTF shown to bind to an activator and the first GTF
implicated in the activation process. The main conflict in the data implicating nucleation
as the stage of initiation altered in activation, is whether activation is equal to the
facilitation of TFIID binding, or whether qualitative changes in the TFIID complex,
induced by the activator and coactivator, result in the facilitation of subsequent steps in
initiation. Both quantitative and qualitative changes may be occurring during the process.
The variable requirement for TFIIA in the process may reflect template differences
whereby different core promoter elements necessitate different TFIID conformations for
activation that are stabilized by TFIIA. Additionally, there may be differential activator
requirements for TFIIA. A combination of the two scenarios is likely as well.
Suggestively, studies in Drosophila cells in culture have shown TFIID occupation of
promoters can be rate limiting on TATA containing but not TATA-less promoters
(Colgan and Manley, 1992). Recently, in vivo experiments in yeast showed that a TBP
mutant that failed to support activation and also failed to bind TFIIA. Activation was
restored by the fusion of the small subunit of yeast TFIIA to the mutant TBP (Stargell
and Struhl, 1995). Further verification in vivo came from the fusion of the yeast TBP to
an exogenous and potent DNA binding domain which generated a hybrid that obviated
the need for activators to achieve stimulated levels of expression (Chatterjee and Struhl,
1995). An analogous in vivo manipulation yielded similar results (Klages and Strubin,
1995). Thus, significant in vitro and in vivo evidence exists supporting the model that
activation occurs at the nucleation step.
Activated assembly of the initiation complex
The effects of activator have been shown to occur post-nucleation (Lin and Green,
1991). In this investigation, an immobilized template transcription system demonstrated
that the assembly of initiation complexes in nuclear extract stalled after the binding of
TFIID, at the TFIIB binding stage. Further, using moderately defined GTFs, activator
was shown to recruit TFIIB to the TFIID complex. Additionally, TFIIB was specifically
retained by immobilized activator but not by point mutant activator (Cress and
Triezenberg, 1990), compromised for activation. Subsequently, the recruitment of TFIIB
by activator was shown to occur in the absence of TAFs where activation would not be
supported (Choy and Green, 1993). Thus activation was not equivalent to TFIIB
recruitment. However, the authors in this study further showed that activator increased
the incorporation of pol II, TFIIF, and TFIIE into the initiation complex dependent on
TAFs. This led to a two step model of activation wherein activator induces a
conformational change in TFIIB that facilitates recruitment of subsequent GTFs in the
pathway. The importance of TFIIB in this process was reinforced by the analysis of
mutants that did not bind activator (Roberts et al., 1993). Here, mutant TFIIBs,
compromised in their ability to bind to Gal4-VP16 and Gal4-AH, supported basal levels
of transcription as wild type, but failed to support activation. Finally, the hypothesized
conformational change in TFIIB was verified by in vitro studies (Roberts and Green,
1994). Recently, experimental findings using holoTFIID gel shift and DNase I
footprinting assays were reported showing that TFIIB binds more stability to the
activated TFIID-TFIIA complex, and further, that TFIIB adds stability to this complex
(Chi et al., 1995). The authors postulated that this dual enhancement of initiation
complex assembly, by multiple activator contacts, may account for transcriptional
synergy.
The data describing the significance of TFIIB interaction with the early initiation
complex in activation are compelling. Interestingly, the conflict over its role in the
process is again a question of quantitative versus qualitative changes in its participation.
Multiple protein-protein interactions between TFIIB and factors critical to activation
including activation domains and TBP, have been elucidated. Further, TAF 40 has been
shown to bind to TFIIB (Goodrich et al., 1993); and maps by protease footprinting, to the
region required for VP16 interaction (Hori et al., 1995). TFIIB may be the pivotal factor
in stimulation, transducing the activating signal from the TFIID-TFIIA complex to foster
the enhanced assembly of the initiation complex.
Clearance
The GTFs that facilitate polymerase clearance, TFIIE and TFIIH, join the
initiation complex at the last stage of assembly. Thus it is formally possible that
clearance is a target of activation, but little evidence has come to light to support this
possibility. Recently the activators VPl6 and p53 were shown to bind to the 62kD
subunit of TFIIH (Xiao et al., 1994). In this report, mutations that decreased activator
potency also decreased retention of TFIIH. The previously described experiments of
Choy and Green (1993) indicated an increased recruitment of TFIIE during activation.
Hence increased promoter clearance could participate in activation.
Elongation
Recently polymerase processivity has been reported to be increased by activators
in vivo (Yankulov et al., 1994). Measuring elongation efficiency through natural pause
sites in from c-myc and HIV-2 TAR, activators were found to boost full-length
elongation. The mechanism for this action and the generality of this phenomenon are
presently unknown. The possibility of activator-influenced elongation also arises from a
study showing the interaction of the TFIIF 74kD subunit with the activator SRF (Joliot et
al., 1995). This interaction may aid in the assembly of the initiation complex or could
increase the elongation effects reported for TFIIF (Flores et al., 1989).
Reinitiation
On the single gene, activation, or increased initiation per time, must alter
reinitiation frequency. The assembly of the initiation complex and the generation of the
first elongation complex differ from the process of reinitiation, which is the reloading of
the TFIID-TFIIA complex that remains promoter bound after the first initiation
(Szentirmay and Sawadogo, 1993; Zawel et al., 1995). Reinitiation does not have to
overcome the proposed slow step of TFIID binding. Nor is it likely to have to rescue the
promoter from nucleosomal repression (Workman and Roeder, 1987). Thus reinitiation
leaves the activator with less work to do to reassemble the complex. Along these lines,
the rerecruitment of TFIIB by activator, after its rapid release from the promoter after
initiation, has been proposed to be a possible activation mechanism (Zawel et al., 1995).
It is possible that different mechanisms are utilized to produce activated initiation
complexes, than to maintain activated reinitiation; there are clearly different slow steps to
each process. The mechanism by which genes are maintained in their activated state is
not yet understood.
Holoenzyme complexes
The recent discovery of partially assembled complexes of GTFs has introduced
the compelling new possibility of single step activation (reviewed in Carey, 1995). The
discovery of coactivating activities in these ensembles has strengthen the proposal that
recruitment of a holocomplex could account for activation. Indeed, single protein-protein
interactions between a holopolymerase complex and a promoter bound factor have been
reported to be sufficient for activation (Barberis et al., 1995). The involvement of such
holopolymerase complexes still allows for activation to occur at the nucleation stage: the
entire complex could then be recruited in one step by an activated TFIID-promoter
structure. The recently described holocomplex in the mammalian system contains TFIID
and was demonstrated to support basal transcription (Ossipow et al., 1995). However,
this complex has not been reported to support activation.
Summary and Introduction to the Thesis
The factors that comprise the basal reaction form a machine that recruits,
accurately positions, and launches RNA polymerase II into transcription. The extent of
factors required for this reaction has been circumscribed, but has some variability
depending on the promoter and the topological conditions. The ability of upstream
regulatory elements to potentiate this reaction depends on additional factors, called
coactivators, whose extent and function are not yet known.
This thesis has sought, through biochemical analysis, to define coactivators and
characterize their function in the reaction; thus asking the fundamental question "what is
the mechanism of activation?" In this thesis, a highly purified in vitro transcription
system was used. This system does not support positive modulation by activators to a
significant degree. In chapter two, the application of this system as a sensitive functional
assay led to the identification of the non-histone chromosomal protein HMG-2 as a
coactivator. The stage of initiation first altered during activation potentiated by HMG-2
was found to be the TFIID-TFIIA binding step. This activating step was not correlated
with an increase in the amount of TFIID-TFIIA complex formed as judged by two
physical methods. Thus the activating event was proposed to involve a qualitative
change in the TFIID-TFIIA complex with activator and HMG-2.
In chapter three data is presented demonstrating that coactivating topoisomerase I
in conjunction with activator enhanced the rate and extent of formation of the TFIID-
TFIIA complex. This is the first physical demonstration of a soluble coactivator
physically altering a stage in initiation of activated transcription. The functional staging
of the transcription reaction exactly correlated with the physical examination of the event
with respect to factor and temporal requirements.
Three sections are appended to the end of this thesis that elaborate on points
brought out in the two main chapters. In the first appendix, the mechanism of repression
of the basal reaction by topoisomerase I in the absence of TFIIA is elucidated. This
repression and its mechanism may be important for a full description of activation in vivo.
In the second appendix, the function of topoisomerase I in activation, based on the
topology of the promoter, is examined. In the final appendix, the ability of three of the
best defined mammalian coactivators to function in the same reaction is determined.
The fourth and final chapter summarizes and examines the conclusions of the
work, focusing on the TFIID-TFIIA complex. The formation of activated initiation
complexes with architectural- factor coactivators is discussed.
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Chapter II
HMG Proteins and Activation of Transcription
This chapter has been adapted for use from the paper
Shykind, B. M., J. Kim, and P. A. Sharp. 1995. Activation of the TFIID-TFIIA complex
with HMG-2. Genes Dev 9: 1354-1365.
which represented a collaboration between Jae Kim and myself.
Abstract
The non-histone chromosomal protein HMG-2 was identified as a factor necessary for
activation in a defined transcription reaction in vitro containing RNA polymerase II and
purified factors. Activation occurred on all promoters assayed except that of the
immunoglobulin IgH gene. TFIIA was required for stimulated levels of transcription.
The activation process depended on the presence of TAFs in the TFIID complex and
generated a preinitiation complex from which TFIIB more slowly dissociated. However,
titration of TFIIB over three orders of magnitude did not obviate the requirement of
activator and HMG-2 to achieve stimulated levels of transcription. Analysis of the
activated reaction identified the TFIID-TFIIA complex as the first stage of modification
during activation. These results suggest that activation can occur solely in the presence
of the basal factors, activator protein, and an "architectural" HMG factor which probably
stabilizes an activated conformation of the TFIID-TFIIA-promoter complex.
INTRODUCTION
The basal reaction for initiation of transcription by RNA Polymerase II (PolIlI) can
be reconstituted with distinct protein factors that assemble on the promoter in an ordered
fashion (reviewed by Buratowski 1994). This process is nucleated by recognition of the
TATA element by TFIID (or the TATA binding protein, TBP) and culminates, after
assembly, with conversion of the initiation complex into the elongation complex. The
basal factors required for this reaction have been purified to homogeneity, and the genes
for many have been cloned. On promoters such as the Adenovirus Major Late (MLP),
this set of factors is comprised of TFIID, TFIIB, TFIIE, TFIIF, TFIIH, and PollI. The
factors TFIIA and TFIIJ can stimulate the basal reaction (Samuels et al. 1982; Cortes et
al. 1992).
Positive modulation of transcription requires additional activities, as reactions
reconstituted with purified basal factors typically do not respond to activators such as SP1
and Gal4-VP16. Coactivating factors enable the basal factors to respond to sequence
specific activators. Stimulation of transcription in vitro is dependent upon the TAF
polypeptides which are associated with the TBP in TFIID (Dynlacht et al. 1991).
Coactivators such as USA (Meisterernst et al. 1991b) and ACF (Merino et al. 1993) are
not associated with TBP. These coactivator fractions potentiate the stimulated reaction.
Some of the components of these complex activities have been purified. The gene
encoding PC4, a positive acting component of USA, has recently been cloned. PC4 is
thought to interact with both basal factors and sequence-specific activators (Ge and
Roeder 1994a; Kretzschmar et al. 1994a). Topoisomerase I also coactivates stimulation
both by repression of basal and potentiation of stimulated transcription (Merino et al.
1993; Kretzschmar et al. 1993). It is possible that the high levels of activation in vivo
are the result of combinations of potentiating and repressing factors (Meisterernst et al.
1991).
The degree of stimulation of transcription by activators is modest in reactions of
defined basal factors and this has made it difficult to determine the functional interactions
of factors necessary for stimulation. In less defined systems, several of the basal factors
have been implicated as targets of activation. Interactions of activator and TFIID fraction
have been shown to yield both quantitative and qualitative effects in the binding of TFIID
to the promoter (Sawadogo and Roeder 1985). The interaction of the TBP component of
TFIID with an acidic activation domain (Stringer et al. 1990) has been proposed as a link
in activation, as mutants in the VPl6 activation domain that reduce function in vivo also
reduce TBP association in vitro (Ingles et al. 1991). Functional assays using partially
fractionated components have suggested TFIIB as a candidate target of activation (Lin
and Green 1991; Choy and Green 1993). Recently, the activator Zta, in the presence of
TFIIA, has been shown to enhance the rate of binding of TFIID to the promoter
(Lieberman and Berk 1994). Additionally, the formation of the TFIID-TFIIA complex
has been suggested to be a rate limiting step in transcription facilitated by activator
(Wang et al. 1992). Genetic and biochemical analysis in yeast suggest a different
important step in activation. Stimulation of transcription in vitro depends on the presence
of a large RNA polymerase II complex composed of general transcription factors, SRB
proteins and polymerase (Koleske et al. 1994; Kim et al. 1994).
Here we report the characterization and identification of a coactivator that
functions in a defined transcription reaction, otherwise unable to respond to sequence-
specific activators. The identification of the coactivator as HMG-2, and the subsequent
demonstration that the HMG-box alone has the same function, suggest a structural role
for these coactivators in establishing the activated initiation complex. The activation
requires TFIIA, and an immobilized template transcription assay defines the TFIID-
TFIIA complex as the first stage of initiation altered during activation.
RESULTS
An activity potentiates activation: Coactivator-B
Reconstitution of transcription with a defined set of basal factors (general
transcription factors, GTFs) resulted in reactions which were not stimulated by the
addition of sequence-specific activators. In these reactions, factors derived from cDNA
clones were used where possible and the remaining purified components were defined
reagents (see Experimental Procedures). Addition of each factor was absolutely required
for transcription (Parvin and Sharp 1993). The degree of stimulation was determined in
reactions that contained both templates with and without binding sites for activators.
Templates of the major late promoter (MLP) with the activator binding sites produced a
390nt transcript while the basal control template which did not contain such binding sites
produced a 180nt message (Figure 1). This reconstituted reaction was active in the basal
reaction but did not show significant stimulation upon addition of Gal4-VP 16. However,
serendipitously, we observed that addition of a third-column fraction derived from a heat-
treated nuclear extract (Chodosh 1988) dramatically boosted transcription in the presence
of the activator Gal4-VP16 from templates containing three Gal4 binding sites (ML-3G),
but not from basal control templates (ML) lacking these sites (Figure 2). Thus the third-
column fraction contained a coactivating activity which was subsequently purified to near
homogeneity with three more chromatographic steps (Figure 3 and Experimental
Procedures). This activity, called coactivator-B (Co-B), coeluted with a protein doublet
of about 30kD. To determine the generality of Co-B as a coactivator, it was tested with
different sequence-specific activators and on different promoters.
Coactivator-B functioned as a potentiator of stimulation with different classes of
transcriptional activators. Addition of either the major late transcription factor (MLTF),
(Figure 4A) or Gal4-VPl6 (Figure 4C) stimulated transcription from the appropriate
template in the presence of Co-B (ML-5M and ML-3G respectively). Furthermore, the
levels of stimulation with Co-B approached those observed in reactions containing
nuclear extract (data not shown and Figure 4B). Co-B preparations were not
contaminated with any basal factors since they were unable to substitute for any of the
these factors , although titration of Co-B gave modest augmentation and then slight
repression of the basal reaction (Figure 4A and C, lanes 1-3). Co-B required the presence
of both activator and activator binding sites to exert its potentiation of stimulation. The
activation observed in these reactions was due to a net increase in transcription from the
specific template and was not due to a selective derepression of the stimulated template
nor to a selective repression of the basal template (compare Figure 4A lanes 4-6).
To characterize the basal machinery requirements for activation, the necessity of
TAFs in the TFIID complex was examined. In almost all in vitro systems tested,
stimulation by activators is dependent upon the presence of the holoTFIID complex
which is composed of TBP and TAFs (Dynlacht et al. 1991; Zhou et al. 1992; reviewed
in Tjian and Maniatis 1994). This was also the case with Co-B; recombinant human TBP
supported basal transcription but did not respond to Gal4-VP16 when Co-B was titrated
into the reaction (Figure 5A). The effect of Co-B on the basal reaction in the presence of
TBP was similar to that observed with holoTFIID: transcription slightly increased and
then similarly decreased as Co-B was titrated into the reaction. Thus, the effect of Co-B
on the basal reaction is TAF independent whereas its effect on the stimulated reaction is
critically dependent on TAFs. This implies that Co-B cannot obviate the need for TAFs
in the stimulated reaction but rather functions as a complementing factor enabling the
stimulatory effect of the activator on the basal machine.
The ability of Co-B to potentiate stimulation in the context of another promoter
was tested. The g-promoter of the heavy chain immunoglobulin gene was substituted for
the MLP upstream of the 390nt G-less cassette. Gal4 binding sites were inserted
upstream of the promoter (gifts of J. Parvin) and the template was tested in the basal and
stimulated reactions with the coactivator. The MLP without binding sites was included
as a control promoter. Surprisingly, Co-B exhibited a different effect on the g-promoter
(Figure 5B). In the absence of Gal4-VP16, Co-B had opposing effects on the two
promoters: transcription from the MLP increased slightly, as was observed in Figure 4,
while transcription mediated by the t-promoter decreased (lanes 1-3). When Gal4-VP 16
was included in the titration, no activation was observed from the g-promoter with its
three Gal4 binding sites. However, at high levels of Co-B, the activator derepressed the
p~-promoter and brought the transcription up almost to the basal level (compare lanes 1, 3
and 6). This is in contrast to the MLP template with Gal4-VP 16 binding sites which was
strongly stimulated by activator as Co-B levels were increased, and suggests that the
activation process potentiated by Co-B involves promoter specific interactions of the
initiation complex, coactivator, and the upstream activator (see Discussion).
Coactivator B is HMG-2
Reverse phase HPLC was used to separate the two polypeptides which comigrated
as approximately 30kD bands in the Co-B preparation (Figure 6A, lane 2). The HPLC
fractions were resolved by SDS-PAGE and silver stained (Figure 6A), and a portion of
each fraction (A-J) was denatured with 6M Guanidine-HC1, renatured (see Experimental
Procedures), and assayed by transcription in the presence of Gal4-VPl6 (Figure 6B).
Fraction C, which contained the peak concentration of the larger polypeptide (Figure 6A,
lane 5) also contained the peak level of coactivator activity. (Figure 6B, lane 5).
N-terminal protein sequencing of the HPLC purified Co-B polypeptide generated
a 21 amino acid sequence which was identical to the amino-terminal sequence of the non-
histone chromosomal protein HMG-2. This nuclear protein also has a molecular weight
of 30kD in SDS-PAGE. To demonstrate that HMG-2 contained the coactivator B
activity, recombinant HMG-2 was produced in bacteria from a human cDNA clone
(Majumdar et al. 1991) and the protein was purified to homogeneity (see Experimental
Procedures). The recombinant protein potentiated activation by Gal4-VPl6 as efficiently
as the original Co-B preparation (Figure 7A). Typically, purified HMG-2 levels of 100Ong
and levels of recombinant HMG-2 of 200ng to 400ng in the transcription reactions gave
saturating amounts of activation, which suggests that only a few molecules of HMG-2 per
template are required for activation (see Discussion). The modest stimulatory activity for
basal transcription observed with the purified, cellular preparation was also observed with
rHMG-2 indicating that this activity was not due to a contaminant.
HMG-1, the cellular homologue of HMG-2, is functionally equivalent in many
assays in vitro (reviewed by Grosschedl et al. 1994). This functional equivalence was
also observed in the activation assay. Recombinant HMG-1 (generous gift of S. Lippard)
was titrated into basal (Figure 7B, lanes 1-3) and Gal4-VPl6 stimulated (lanes 4-6)
transcription reactions. The coactivation by rHMG-1 suggested that a common feature of
the HMG-1/2 family was responsible for such activity. The most striking common
features of this family are subdomains which non-specifically bind DNA in the minor
groove. These sub-domains, called HMG-boxes, are repeated twice in HMG-1/2. The
HMG-box from the B-domain of HMG-1 is a folded polypeptide of about 80 amino acids
that binds and dramatically bends DNA (Pil et al. 1993). A purified recombinant peptide
corresponding to this domain (generous gift of S. Lippard) was assayed in the
reconstituted reaction and was functionally equivalent to HMG-1 (Figure 4B, lanes 7-12).
Thus the sequences necessary for DNA binding by HMG-1/2 are also sufficient for
coactivation of transcription. As a further demonstration of the generality of HMG-1/2
coactivation, the human heat shock promoter (HuHSP) with three upstream Gal4 sites
(gift of J. Parvin) was assayed with the recombinant HMG-2 preparation (Figure 7C). As
was observed for the MLP, rHMG-2 similarly coactivated Gal4-VP16 stimulation on this
promoter.
The identification of HMG-1/2 as a coactivator of PollI transcription in a defined
in vitro system containing purified general transcription factors made it possible to study
the mechanism of activation. The stimulated reaction was analyzed by titration of basal
factors, and by characterization of the effects of activation on individual steps in
initiation.
TFIIA and TFIIB in activation
Consistent with previous observations (Ma et al. 1993), TFIIA only slightly
augmented the basal reaction in the purified system used in these experiments. More
recently, TFIIA was shown to be required, or to enhance in vitro activation in systems of
transcription factors of varying purity (Ozer et al. 1994; Yokomori et al. 1994; Sun et al.,
1994). The requirement for TFIIA in activation potentiated by HMG-1/2 was tested
(Figure 8A). Titration of TFIIA in the absence of HMG-1/2 but in the presence of
activator slightly increased the level of transcription both from templates with and
without Gal4 sites (lanes 1-3). More interestingly, no stimulation was observed in the
absence of TFIIA when HMG-1/2 and Gal4-VPl6 were present (compare lanes 1 and 4).
To achieve significant levels of stimulation both HMG-1/2 and TFIIA were required in
the presence of activator (lanes 4-6). Thus TFIIA is essential for stimulation of
transcription by Gal4-VPl 16 in the presence of HMG-1/2.
The potential importance of TFIIB binding in activation has been described (Lin
and Green 1991; Choy and Green 1993). However, some experiments suggest that at
least part of the activation process precedes the interaction of TFIIB with the template
bound TFIID complex (White et al. 1992). If the function of activators and coactivators
were to increase a rate limiting TFIIB binding step during initiation, then increasing the
concentration of TFIIB should reduce the level of stimulated versus basal transcription.
The concentration of TFIIB was titrated over three orders of magnitude (Figure 5B).
High levels of TFIIB did not obviate the need for activator or HMG-1/2 to attain
significant levels of stimulation. In fact, as the concentration of TFIIB increased,
transcription from the ML-3G template in the absence of HMG-1/2 saturated at lower
concentrations of TFIIB than in the presence of HMG-1/2. This increase in the degree of
stimulation with increased TFIIB concentration was also observed by Choy and Green
(1993) in a TFIIB-depleted nuclear extract and suggests that activation of transcription is
not equivalent to an increased affinity of the initiation complex for TFIIB.
Staged reactions on immobilized templates
The step in the assembly of the initiation complex affected by activation can be
partially characterized by an immobilized template system (Lin and Green 1991). By
tethering the templates to magnetic beads, distinct complexes formed on the template can
be purified from unbound or loosely associated factors and tested for transcriptional
activity with the subsequent addition of other factors and nucleotides. Figure 9
summarizes the technique. Briefly, template DNA was end-labeled with a single
biotinylated deoxynucleotide and then bound to streptavidin covalently linked to
paramagnetic beads. Typically two incubations are done. The first incubation, the "pre-
inc," allows the formation of a distinct preinitiation complex on the promoter. The
complexes formed in the pre-inc are then washed to remove uncommitted factors. In the
second incubation, the "chase," the remaining transcription factors are added along with
nucleotides. Thus the effect of stimulation on the activity of basal factors in the
formation of stable preinitiation complexes can be determined by preincubation of
different combinations of factors.
In the presence of both activator and HMG-1/2, stimulation of transcription
resulted in an increased formation of active preinitiation complex (Figure 10A). In lanes
1 and 2, all the general transcription factors (GTFs) were pre-incubated with and without
Gal4-VP16 (G) respectively, washed, and chased with nucleotide triphosphate under
transcription conditions. Gal4-VP16 had no effect on the formation of initiation
complexes until HMG-1/2 was added during the pre-inc (compare lanes 2 and 4). In
figure 10B, the basal factors and HMG-1/2 were pre-incubated in the presence and
absence of the activator MLTF. As was observed with Gal4-VP 16, the amount of active
preinitiation complex was increased only if the activator was present in the pre-inc.
Additionally, lanes 3 and 4 show that the addition of ATP during the pre-inc did not alter
the amount of stimulation. If HMG-1/2 was added both in the pre-inc and afterwards in
the chase no change in the level of stimulation was observed. This strongly argues that
the positive effect of HMG-1/2 does not require ATP hydrolysis and acts during
preinitiation and not at a post-initiation step.
Activation occurs at the TFIID-TFIIA complex stage
To determine the first step of initiation altered by activation, activator and HMG-
1/2 were added together at distinct steps in the assembly of the initiation complex
(Figure 11). Activation was observed when all factors including activator and HMG-1/2
were added together in the chase, but was not observed if the activator and HMG-1/2
were pre-incubated with template (compare lanes 1 and 2). This indicates that HMG-1/2
is probably not simply stabilizing the binding of activator on the template. When TFIID
was pre-incubated on the template with HMG-1/2 and Gal4-VP16 (lane 4) or committed
alone and then chased with both (lane 3), no activation was observed. This indicates both
that TFIID alone is not recruited to the template during activation and that template
committed TFIID does not subsequently support activation. However, when TFIIA and
TFIID were pre-incubated in the presence of activator and HMG-1/2, stimulation was
observed (compare lanes 5 and 6). These results are consistent with the previous finding
that TFIIA was essential for activation (Figure 8A).
Lin and Green (1991) have reported that TFIIB more stably associates with TFIID
in the presence of activators. Further, they have suggested that the direct interaction of
TFIIB with activator promotes the association of this protein with TFIID (Choy and
Green 1993). As shown by a comparison of lanes 7 and 8, preincubation of the activator,
HMG-1/2, and TFIID did not significantly increase the stable association of TFIIB.
However, consistent with the phenomenology of the Lin and Green (1991) result,
preincubation of TFIIB with TFIID and TFIIA under activating conditions resulted in a
more stable association of TFIIB (compare lanes 9 and 10). This enhanced association
clearly occurs either after or simultaneously with the formation of the activated TFIID-
TFIIA complex and may reflect a difference in the conformation of the activated versus
basal complexes. These data suggest that retention of TFIIB on the TFIID complex is not
the first step in activation but that activation precedes this step, at the stage of interaction
of activator, coactivator, TFIID, TFIIA and template.
Electrophoretic Mobility Shift Assay (EMSA) was used to investigate the stability
of TFIID-TFIIA complexes after activation by activator and HMG-2. Interestingly, no
quantitative differences were observed in the formation of TFIID-TFIIA complex under
activation conditions in the presence of HMG-2 and Gal4-VP16 (Figure 12). HoloTFIID
and radio-labeled MLP with three Gal4 sites fused upstream were coincubated with
combinations of TFIIA, HMG-2 and Gal4-VP16 and then subjected to EMSA on agarose
TBE gels. Essentially no TFIID complex was detected in the absence of TFIIA even in
the presence of activator and HMG-2 (lanes 1-4). In the presence of TFIIA a stable
TFIID-TFIIA complex formed. This complex was slightly altered in mobility when
coincubated with Gal4-VP16, however, no significant change was observed in the TFIID-
TFIIA complex if HMG-2 was included with Gal4-VP16 (lanes 5-8). These last
conditions generated activation in the previous transcription assays. These results suggest
that during the activation process no quantitative change occurs in the formation of the
TFIID-TFIIA complex.
The state of the TFIID-TFIIA complex on the promoter under basal and activating
conditions was also examined using DNase I footprint analysis. No significant changes
in either the extent of the footprint or its strength were observed when HMG-2 and
activator were coincubated with TFIID and TFIIA on the template (Figure 13). As
expected, the TBP-TFIIA complex protected the TATA region from -35 to -20 (lane 3).
Both the TBP-TFIIA and the TFIID-TFIIA complexes stabilized Gal4-VP16 binding,
increasing the strength of the footprint over the Gal4 binding sites. HMG-2 did not alter
the TBP-TFIIA footprint (compare lanes 3 and 5). As has been reported (Sawadogo and
Roeder 1985; Lieberman and Berk 1994), the TFIID-TFIIA complex gave an extended
footprint of protected and hypersensitive sites downstream of the TATA box from -35 to
+40 (compare lanes 3 and 4 with 7 and 8). However, no alteration of the footprint was
observed when HMG-2 was added, either alone or with activator, in the TFIID-TFIIA
binding reaction (compare lanes 7 and 8 with 9 and 10). Thus, under activation
conditions, the presence of activator and HMG-2 did not alter the footprint of the TFIID-
TFIIA complex on the promoter.
Discussion
We have purified a factor important for activation and identified it as HMG-2.
Interestingly, the activity of HMG-2 is specific for some promoters. Activation of
transcription requires the presence of TFIIA, and the early initiation complex composed
of TFIID and TFIIA is modified by interaction with activator and HMG-1/2. Similar to
activation in total extracts and in partially fractionated systems, stimulation of
transcription in this system depends upon the presence of TAFs in the holoTFIID
complex (Dynlacht et al. 1991; Zhou et al. 1992) and results in a change in the nature of
the interaction of TFIIB with the activated preinitiation complex. We propose that this
activation step involves the induction of a structure in the TFIID-TFIIA-promoter
complex which facilitates initiation.
HMG-1 and HMG-2 function interchangeably in reactions containing the major
late promoter. In fact, the HMG-box from the B-subdomain of HMG-1 functions
indistinguishably from the full-length protein. This subdomain consists of 80 amino
acids folded into three oa-helices arranged roughly into an L-shape (Weir et al. 1993;
Read et al. 1993). The HMG-box, as well as HMG-1 and 2 bind DNA in the minor
groove and bend the helix toward the major groove (reviewed by Grosschedl et al. 1994).
Since the HMG-box subdomain alone enables activation in the system, it is likely that
these proteins function by stabilizing conformations of DNA bound to the basal factors
and activator. These critical conformations could involve looping of the activator to the
basal complex, or altering of the local topology of the DNA around the basal factors
(Bazett-Jones et al. 1994; Giese et al. 1992; Paull et al. 1993).
The HMG-1/2 proteins dramatically enhanced activation in reactions containing
the MLP or the HSP but suppressed transcription in reactions containing the IgH t-
promoter. Maximal activation was observed at a HMG-2 to template ratio of
approximately 100 to 1, an absolute concentration of HMG-2 of 150 nM. Based on the
reported affinity of HMG-1/2 for dsDNA (Pil and Lippard 1992), this ratio represents
only a few molecules of bound HMG-1/2 per template DNA. The template specificity of
HMG-1/2 must reflect a difference in the sequence of these promoters and consequently a
difference in the nature of their interactions with protein factors. For example, such
specificity could be due to a sequence preference for the binding of the HMG-box to the
MLP or HSP templates. However, HMG-1/2 binds DNA with little or no direct sequence
specificity other than binding to DNA with irregular or bent structures (reviewed by
Bustin et al. 1990; Grosschedl et al. 1994 and references therein). More likely, the
template specificity reflects the dependence of a critical activation complex on the
enhanced stability conferred by the HMG protein. For example, a hypothetical activated
conformation of the TFIID-TFIIA complex could be dependent upon the topology of the
promoter stabilized by HMG-1/2. We favor this latter possibility since the IgH g-
promoter was not activated at any concentration of HMG-2 and its basal activity was in
fact repressed by low concentrations of HMG-1/2.
Activation was first detected at the stage of the interaction of TFIID, TFIIA,
HMG-2, and activator in the presence of template. This activated complex is
distinguishable by a decrease in the rate of dissociation of TFIIB and a more efficient
assembly of a transcriptionally active polymerase complex. However, activation is not
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In the defined reconstituted reaction, association of TFIID and template in the
absence of TFIIA rendered this complex refractory to subsequent activation, but still able
to support the basal reaction. The refractory nature of the template committed TFIID
suggests that the conformation of TFIID-promoter complexes can vary. This observation
is similar to previous results where template committed TFIID complexes were unable to
respond to the addition of an activator (Wang et al. 1992). Those complexes formed in
the absence of activator, which were referred to as "inactive" by Wang et al., may in fact
be locked in a conformation that only supports basal levels of transcription.
Consistent with all of the above results, the activation event probably involves a
conformational change in the TFIID-TFIIA complex, possibly involving an alternate
arrangement of the TAFs on the template (Figure 14). The activation event may expose
multiple or altered binding sites for TFIIB that in turn stabilize a specific conformation of
TFIIB. This conformation of TFIIB could more efficiently recruit the other proximal
basal factors for initiation. Such a conformational change in TFIIB has been postulated
(Choy and Green 1993; Roberts and Green 1994), and mutants in TFIIB exist that support
basal but not stimulated transcription (Roberts et al. 1993). It is also likely that the
activated TFIID-TFIIA-template conformation preferentially interacts with basal factors
beyond TFIIB in initiation. In fact, a polymerase II holoenzyme complex, such as that
defined in yeast (Koleske and Young 1994), could be recruited through multiple
interactions with the activated TFIID-TFIIA complex.
In this system, HMG-1/2 allows the basal reaction to respond to activators
although it is probably acting by a different mechanism than the factors previously
defined as coactivators. The soluble, non-TAF, coactivators described to date, while not
essential for the basal reaction, can modulate this reaction in the absence of activators,
possibly altering the TFIID-TFIIA interaction. The defined transcription reaction
described here which mediates activation with HMG-1/2 does not contain any of the
known soluble coactivators. The USA component, PC4 has been shown to interact with
the basal factors and with the activation domains of activators and thus is probably acting
as an "adapter" molecule, physically linking the activator and the basal machine. HMG-1
does not interact with activators (Ge and Roeder 1994b; our unpublished data), but has
been reported to form a complex with TBP on the promoter (Ge and Roeder 1994b).
Interestingly HMG-1/2 has been reported to repress both the basal and stimulated
reactions in vitro (Ge and Roeder 1994b; Stelzer et al. 1994). We have found that the
presence of either topoisomerase I or the USA component PC4 alter reactions such that
HMG-1/2 represses transcription upon titration (see Appendix C).Topoisomerase I/PC3
antagonizes the formation of the TBP-TFIIA complex on the promoter (Merino et al.
1993), and thus could alter the nature of the interaction of activators with the TFIID-
TFIIA complex. The enzymatic activity of topoisomerase I is dispensable for its
repression of transcription (Merino et al. 1993).
HMG-1 and HMG-2 are the founding members of a family of DNA binding
proteins involved in transcription including LEF-1 (Giese et al. 1992), SRY (Ferrari et al.
1992), hUBF (Jantzen et al. 1992) and DSP-1 (Lehming et al. 1994), all of which contain
one or more HMG-boxes (reviewed by Grosschedl et al. 1994). The ability of the HMG-
box containing factors to modulate DNA conformation has led to the description of this
family as "architectural" transcription factors (Wolffe 1994). That HMG-1/2 potentiates
stimulation in the presence of purified basal factors and activator suggests that the
activation step does not require components beyond the basal machinery, activator, and
an "architectural" factor. We propose that this activation step involves the stabilization
by the HMG-1/2 proteins of a specific conformation of the TFIID-TFIIA-activator
complex that facilitates enhanced rates of initiation.
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Figure 1
Transcription templates. Three Gal 4 sites fused upstream of either the adeno major late,
the IgH g, or the huHSP promoter, or five MLTF sites fused upstream of the major late
promoter were used as activatable test promoters. The major late promoter driving a
180nt G-less cassette was used as the basal control promoter.
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Figure 2
Third column fraction contains a coactivator
ML transcript (180nt) was generated by 25ng supercoiled MLP basal control promoter.
ML-3G transcript (390nt) was generated by 25ng supercoiled MLP with three Gal4
binding sites fused upstream. Lanes 1-3: titration of fraction (0, 0.5, 1.5pl) into the
reaction in the absence of Gal4-VP16. Lanes 4-6: titration of fraction (0, 0.5, 1.5p.l) into
the reaction in the presence of saturating amounts of Gal4-VP16 (G).
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Purification of coactivator B
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Figure 4. Ability of coactivator-B to stimulate transcription with different activators.
(A) Activity with the cellular activator MLTF (M). ML transcript (180nt) was generated
by 25ng supercoiled MLP basal control promoter. ML-5M transcript (390nt) was
generated by 25ng supercoiled MLP with five MLTF binding sites fused upstream.
Transcripts were separated by urea-PAGE. Lanes 1-3: titration of Co-B (0, 1, 5p•l) into
the reaction in the absence of activator. Lanes 4-6: titration of Co-B (0, 1, 5 kl) into the
reaction in the presence of saturating amounts of MLTF (M). (B) Quantitation of
stimulation from reactions shown in figure 1A was by Phosphorimager (Molecular
Dynamics, Inc.). Fold stimulation is expressed as the ratio of message generated by ML-
5M template versus that generated by ML template.
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Figure 4C.
Effect with the synthetic activator Gal4-VP16. ML transcript (180nt) was generated by
25ng supercoiled MLP basal control promoter. ML-3G transcript (390nt) was generated
by 25ng supercoiled MLP with three Gal4 binding sites fused upstream. Lanes 1-3:
titration of Co-B (0, 1, 5jl) into the reaction in the absence of Gal4-VP16. Lanes 4-6:
titration of Co-B (0, 1, 54l) into the reaction in the presence of saturating amounts of
Gal4-VP16 (G).
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Figure SA. Stimulation of activation by coactivator-B requires TAFs in the holoTFIID
complex.
Titration of Co-B (0, 1, 5tl) into transcription reactions with TBP in the absence (lanes 1-
3) and presence of Gal4-VP16 (G), (lanes 4-6). ML transcript (180nt) was generated by
25ng supercoiled MLP basal control promoter. ML-3G transcript (390nt) was generated
by 25ng supercoiled MLP with three Gal4 binding sites fused upstream.
5B. Template specificity of coactivator-B.
Titration of Co-B (0, 1, 2ýtl) into transcription reactions in the absence (lanes 1-3) and
presence (lanes 4-6) of Gal4-VP16 (G). ML transcript (180nt) was generated by 25ng of
supercoiled MLP basal control template. Ig-3G transcript (390nt) was generated by 25ng
supercoiled Ig heavy-chain t-promoter with three Gal4 sites fused upstream.
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Figure 6. HPLC purification of Co-B and transcriptional activity of renatured fractions.
(A) Purified Co-B preparation was subjected to reverse phase HPLC using a C4 column
and fractions were resolved in a 14% SDS-PAGE and silver stained. Lane 2: load
material and lanes 3-12 : HPLC fractions A-J respectively. (B) HPLC fractions and load
were denatured with 6M guanidium-HC1, renatured by dialysis and assayed by
transcription in the presence of Gal4-VP16. Lanes 3-12: HPLC fractions A-J, with load
material (L) assayed in lane 2 and buffer added to reaction in lane 1. ML transcript
(180nt) was generated by 25ng of supercoiled MLP basal control template. ML-3G
transcript (390nt) was generated by 25ng of supercoiled MLP with three Gal4 binding
sites fused upstream.
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Figure 7. Recombinant HMG-1 and HMG-2 proteins coactivate stimulation.
(A) Recombinant human HMG-2 protein was titrated into transcription reactions at Ong,
100ng 500ng, in the absence (lanes 1-3) and the presence (lanes 4-6) of Gal4-VP16 (G).
ML transcript (180nt) was generated by 25ng of supercoiled MLP basal control template.
ML-3G transcript (390nt) was generated by 25ng supercoiled MLP with three Gal4
binding sites fused upstream.
(B) Recombinant rat HMG-1 and recombinant HMG-1 B-subdomain were titrated into
reactions in the absence (lanes 1-3 and 7-9) and the presence (lanes 4-6 and 10-12) of
saturating amounts of GaI4-VP16 (G), at Ong, 100ng, and 500ng of HMG-1 and Ong,
50ng, and 250ng of the B-domain polypeptide. ML transcript (180nt) was generated by
25ng of supercoiled MLP basal control template. ML-3G transcript (390nt) was
generated by 25ng supercoiled MLP with three Gal4 binding sites fused upstream.
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Figure 7C Recombinant HMG-2 coactivates stimulation on the human HSP promoter.Recombinant human HMG-2 protein was titrated into transcription reactions at Ong,100ng 500ng, in the absence (lanes 1-3) and the presence (lanes 4-6) of Gal4-VP16 (G).ML transcript (180nt) was generated by 25ng of supercoiled MLP basal control template.ML-3G transcript (390nt) was generated by 25ng supercoiled HuHSP with three Gal4binding sites fused upstream.
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Figure 8. Roles of TFIIA and TFIIB in activation.
(A) TFIIA is required for activation by coactivator B. Homogeneous preparation of
purified human TFIIA was titrated into transcription reactions at 0, 0.5, and 5g1, in the
absence (lane 1-3) and the presence (lanes 4-6) of purified HMG-2 (pHMG-2). Gal4-
VP16 was added to each reaction. ML transcript (180nt) was generated by 25ng of
supercoiled MLP basal control template. ML-3G transcript (390nt) was generated by
25ng supercoiled MLP with three Gal4 binding sites fused upstream. (B) Titration of
rTFIIB. Recombinant human TFIIB was titrated into transcription reactions in the
absence (odd numbered lanes) and the presence (even numbered lanes) of pHMG-2.
Gal4-VP16 was added to each reaction. ML transcript (180nt) was generated by 25ng of
supercoiled MLP basal control template. ML-3G transcript (390nt) was generated by
25ng supercoiled MLP with three Gal4 binding sites fused upstream.
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Figure 10. Preinitiation complex formation is increased in the presence of activator and
HMG-2.
(A) Linear MLP template containing the 390nt G-less cassette with three Gal4 binding
sites fused upstream was biotinylated at one end and bound to magnetic streptavidin
beads. The general transcription factors were incubated with template bound beads alone
(lane 1), with Gal4-VPl6 (G), (lane 2), with pHMG-2 (lane 3), or with both Gal4-VP16
(G) and pHMG-2 (lane 4), for 60 min. at 300C. Complexes formed on the template-
beads were washed and nucleotides were added under transcription conditions. (B)
Template-beads of the MLP with five MLTF binding sites fused upstream of the 390nt
G-less cassette were prepared as described above. General transcription factors and
pHMG-2 were incubated in the absence and presence of saturating amounts of purified
MLTF (M) as described above. ATP was added in this preincubation to 0.1mM in lanes
3 and 4. Complexes formed were washed and nucleotides were added under transcription
conditions in the chase step. Additionally, pHMG-2 was added again in the chase , in
lanes 5 and 6.
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Figure 11. Activation occurs at the TFIID-TFIIA complex.
Linear MLP template with three Gal4 binding sites was biotinylated and bound to
magnetic beads as described (Experimental Procedures, Figure 6 legend). General
transcription factors including homogeneously purified human TFIIA were used to form
the preinitiation complexes: TFIID (lanes 3-4), TFIID-TFIIA (lane 5-6), TFIID-TFIIB
(lanes 7-8) and TFIID-TFIIA-TFIIB (lanes 9-10). Gal4-VP16 (G) and pHMG-2 were
incubate with the particular factors in the pre-inc (even numbered lanes) or added after
complex formation in the chase along with the remaining general factors and nucleotides
(odd numbered lanes).
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Figure 12. Formation of the TFIID-TFIIA complex.
Radio-labeled MLP probe was incubated with TFIID and various combinations of
homogeneously purified TFIIA, rHMG-2 and Gal4-VP16 under conditions consistent
with activated transcription and analyzed by electrophoresis in 1.6% agarose-TBE gels
(Lieberman and Berk, 1994).
Figure 13. Footprint of the TFIID-TFIIA complex. (following page)
The DNase I footprint pattern of TBP-TFIIA and TFIID-TFIIA complexes were
analyzed with various combinations of pHMG-2 and Gal4-VP16. Binding reactions were
identical to those used in figure 8.
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Model of HMG coactivation.
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Materials and Methods
Purification of Co-B
The preparation of crude MLTF fraction, HBrBC, which contained HMG-2, was
described in detail previously (Chodosh 1988) and is briefly summarized here. Nuclear
extract was made from homogenized calf brain with minor modifications to the Dignam
method. The extract was equilibrated in buffer A (20 mM Hepes-NaOH [pH 7.9], 20%
glycerol, 1 mM EDTA, 1 mM DTT, and 1 mM phenylmethylsulfonyl fluoride) + 100
mM KCl + 0.03% Nonidet P-40 and heated at 800 C for 35 minutes with continuous
stirring. After cooling to room temperature and centrifugation, the supernatant was
loaded onto a DEAE-Sepharose column equilibrated in buffer A + 100 mM KCl + 0.03 %
NP-40. The column was sequentially washed with 3 column volumes of buffer A + 100
mM KC1, 3 column volumes of buffer A + 250 mM KC1, and 3 column volumes of buffer
A + 500 mM KC1. MLTF activity, assayed by EMSA, was found in the 250 mM step
(HBrB). Heparin-Sepharose (Pharmacia) was prepared according to the manufacturer's
instructions and was equilibrated in buffer A + 100 mM KC1. After loading the HBrB,
the column was washed sequentially with 3 column volumes of buffer A + 100 mM KC1,
3 column volumes of buffer A + 250 mM KC1, and 3 column volumes of buffer A + 500
mM KC1. MLTF was found in the 500 mM KCl step (HBrBC).
Phosphocellulose (Whatman P 11) matrix (1.3 ml) was prepared according to the
manufacturer's instructions and equilibrated with buffer A + 200 mM KC1. HBrBC (7
mgs in 7.5 mls) was batch absorbed and sequentially washed with 4 column volumes of
buffer A + 200 mM KC1, 4 column volumes of buffer A + 350 mM KC1, 4 column
volumes of buffer A + 600 mM KCI, and 4 column volumes of buffer A + 1 M KC1. The
MLTF was found in the supernatant of binding and 350 mM KCl step. The Co-B
activity, found in the 600 mM KCI step, was dialyzed to buffer A + 100 mM KCI and
loaded onto a
Mono Q HR 5/5 column (FPLC, Pharmacia ). The bound material was eluted with a 12
ml linear gradient of 100 to 400 mM KCI in buffer A. The activity was eluted near 300
mM KC1. The active fractions were dialyzed to buffer A + 1.2 M ammonium sulfate and
loaded onto a phenyl sepharose HR 5/5 column (FPLC, Pharmacia). The loaded material
was eluted with a 12 ml linear gradient of 1.2 M to 0 M ammonium sulfate in buffer A.
The activity, found in the flowthrough, was dialyzed to buffer A + 100 mM KCI and
loaded onto a Mono S HR 5/5 column (FPLC, Pharmacia). From a 12 ml linear gradient
of 100 mM to IM, the peak of the activity was found near 200 mM KC1. Further
processing of the purified material for renaturation and amino acid sequencing was done
using a C4 reverse phase column ( HPLC system, HP Model 1090M, part #214TP52)
Renaturation of HPLC Fractions
Each of the fractions from the C4 column was brought to 0.1M Hepes [pH 7.9],
frozen, and then lyophilized. To each fraction, 15 p•l of denaturation buffer ( 6 M
Guanidine-HC1, 50 mM Tris [pH 7.9], 0.1 mM EDTA, 10% glycerol, 50 mM NaC1, 2
mM DTT) was added to thoroughly solubilize the dried material. After incubating at
room temperature for 15 minutes, 105 p•l of dilution buffer ( 50 mM Tris [pH7.9], 5%
glycerol, 150 mM KC1, 0.1 mg/ml Bovine Serum Albumin, 0.1 mM EDTA, 2 mM DTT)
was added. Fractions were dialyzed overnight to buffer A + 100 mM KCl at 40C.
Amino Acid Sequencing of Co-B
N-terminal sequencing of the sole polypeptide in the active renatured fraction
(fraction C) was carried out on an Applied Biosystems Model 477A Protein Sequencer
with on-line Model 120 PTH Amino Acid Analyzer. The N-terminal 21 amino acids
revealed a sequence which matched that of the High Mobility Group 2 (HMG-2) protein
from several species including bovine HMG-2 (See Results).
Expression of HMG-2 in E. coli
A pair of primers bearing the N-terminal and C-terminal ends of HMG-2 coding
sequence flanked by Bam H1 restriction sites were generated ( N-terminus,
5'-dGCACGGATCCAGGTAAAGGAGACCCCAACAAGCCG-3'; C-terminus, 5'-
dGCACGGATCCTCATTATTCTTCATCTTCATCCTCTTCCT-3'). These
oligonucleotides were used to generate a PCR product containing the complete coding
sequence of human HMG-2 using a cDNA clone (a gift of M. Seidman of Otsuka
Pharmaceuticals; Majumdar et al., 1991) as the template. The PCR product was digested
with Bam H1 and cloned into pET-15b (Novagene). E. coli strain BL21DEpLysS
(Novagen) containing pHMG-2 was grown in LB medium supplemented with 150 pg/ml
of ampicilin. Upon reaching an O.D. 600 of 0.6, HMG-2 was induced with 1 mM IPTG
for 3 hours. The harvested cells were resuspended in buffer L ( 20 mM Tris [pH 7.9],
200 mM NaC1, 20 mM P-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride; 20 mls
per liter of culture) and lysed by sonication. Induction and subsequent purification of
HMG-2 were followed by western assay with polyclonal antibody against rat HMG-1
(gift of S.Lippard). The supernatant of the lysis was sequentially precipitated with 45%
and 75% ammonium sulfate. HMG-2, found mostly in the 75% ammonium sulfate
precipitate, was dialyzed to buffer N (20 mM Hepes [pH7.9], 20% glycerol, 7 mM J-
mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride + 0.1% Nonidet P-40) + 5 mM
imidazole + IM KC1. This was batch absorbed onto a 1 ml of Ni-NTA resin (Qiagen).
The matrix was poured into a small column and washed with 10 column volumes of
buffer N + 100 mM KC1. HMG-2 was subsequently eluted with buffer N + 250 mM
imidazole +100 mM KC1. The peak of activity was dialyzed to buffer A + 500 mM KC1
and loaded onto a Superdex 200 16/60 column (FPLC, Pharmacia). The active fractions
were dialyzed to buffer A +100 mM KCl and loaded onto a Mono Q HR 10/10 column
(FPLC, Pharmacia). A linear gradient elution from 100 mM to 1M KC1 resulted in a
homogenous recombinant HMG-2 preparation.
In vitro transcription
Preparation of the recombinant transcription factors, TBP, IIB, IIB, and IIF has
been described (Parvin et al. 1994). Purification of holo-TFIID was done essentially as
described (Zhou et al. 1992). RNA polymerase II was the highly purified preparation
from a CHO cell line (Carthew et al. 1988). The source of TFIIA was either IIA fraction
(Parvin et al. 1994) or a homogenous preparation of TFIIA. The latter was prepared
following the steps of a previously published purification through the single-strand-DNA
agarose chromatography step (Cortes et al. 1992). The active fractions were purified to
homogeneity with Ni-NTA resin (Qiagen). TFIIH was purified from HeLa-nuclear-
extract-derived fraction Cl (Parvin et al. 1992). The purification was followed by
western assay using an antibody to the p62 subunit (gift of J. Egly; Fischer et al. 1992).
C1 fraction (80 mg in 50 ml) in buffer A + 100 mM KCl was loaded onto a Mono Q HR
10/10 column (FPLC, Pharmacia). An 80 ml linear gradient from 100 mM to 600 mM
KCl was used to elute the TFIIH complex. The peak fractions, near 230 mM KC1, were
dialyzed to 1.0 M ammonium sulfate in buffer A and loaded onto a phenyl sepharose HR
5/5 column (FPLC, Pharmacia). The loaded material was eluted with a linear gradient
from 1.0 M to 0 M ammonium sulfate in buffer A. The activity, found near 300 mM
ammonium sulfate, was dialyzed to buffer A + 500 mM KCl and loaded onto a Superdex
200 16/60 column(FPLC, Pharmacia). TFIIH, by western assay and transcription, was
found to have an apparent size of 700 kD. Gal4-VP16 was prepared as described
(Chasman et al. 1989). Rat HMG-1 and rat HMGI-boxB were kind gifts of S. Lippard
(Pil and Lippard 1992). MLTF used in the transcription assay was the Phosphocellulose
flowthrough fraction described above.
DNA templates for transcription in vitro, Gal4(3)-MLP, and MLTF(5)-MLP, were
gifts of H. Timmers and S. Harper, respectively. Gal4(3)-pt and Gal4(5)-HSP were gifts
of J. Parvin. The control template MLP has been described (Timmers and Sharp 1991).
The conditions for the assay and typical amounts of basal transcription factors used were
as previously described (Parvin et al., 1994). Where indicated, 10 ng of Gal4-VP16, I gl
of MLTF fraction, and 100Ong to 500ng of purified or cloned HMG-1/2 preparations were
added.
The immobilized templates were generated by cutting the appropriate templates
with Xmn I and Nde I followed by Klenow end-filling with biotin-16-dUTP (Boehringer-
Mannheim) and dATP (100 gM each). The gel-purified 2500 bp long fragment was
incubated with streptavidin-coupled M-280 Dynabeads (Dynal Inc., 10 pl of slurry per
100 ng of DNA) for 60 minutes. The DNA coupled resin was washed and stored in
buffer A + 100 mM KC1 + 0.1 % Nonidet P-40 in the original volume.
Staged transcription assays were typically done as follows. The DNA coupled
resin (10 gl) was incubated with the "pre-inc" factors for 60 minutes at 30 oC in buffer A
+ 100 mM KC1 + 0.1 % Nonidet P-40 + 5 mM MgCl2 ( total volume, 20 p•l). The
protein-DNA complexes were washed with 300 p•l of the incubation buffer. The "chase"
factors and nucleotides were added subsequently, and the reaction was brought to the
transcription condition (see above). The incubation was continued for 90 minutes at 30
oc.
EMSA and DNase I Footprinting
A pair of primers were generated to produce a 260 bp PCR product from a
Gal4(3)-MLP transcription template:
(5'dGACCATGATTACGCCAAGCTTGCATGCCTGC-3',
5'-CGCTACTCGAGAGGAATAATGAGGAAAGGAGAGTAG-3'). The PCR product,
covering the regions -180 to +65 of the promoter region, were digested with HindIII and
XhoI and inserted into pBSII-SK+. The probe for EMSA and DNase I footprinting was
generated by cutting the plasmid with Hind III, Klenow-end filling with [3 2 P] dATP, and
then cutting with Xho I. Protein-DNA-binding reactions were done following the
published protocol (Lieberman and Berk 1994) with several modifications. Binding was
done in 16 p1 of binding buffer (12.5mM Hepes [pH7.9], 12.5 % Glycerol, 6.25 mM
EDTA, 70 mM KCI, 10.8 mM P3-mercaptoethanol, 0.5 mg/ml BSA, 5 gg/ml poly(dGdC),
and 1 ng of probe) at 300 C for 30 min. Gels for EMSA were cast with 1.6 % agarose in
0.5X TBE with 6.25 mM MgCl2. The gel was run in 0.5X TBE with 6.25 mM MgCl2 at
70 volts for 5 hours and then dried on DE81 paper. For the DNase I footprinting assay,
16 •1 of DNase I solution containing 1 ng of DNaseI (Worthigton Enzymes; DPFF grade)
and 5 mM CaC12 were added to the binding reaction above. After 1 minute of incubation
at room temperature, 90 gl of stop solution (20 mM EDTA [pH8.0], 1%SDS, 200mM
NaC1, 250gg/ml yeast tRNA) was added. The DNase I digestion was analyzed by
sequencing gel electrophoresis.
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Chapter III
DNA Topoisomerase I in Activation of Transcription
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Abstract
DNA topoisomerase I was shown to potentiate activation of Pol II transcription in a
highly purified in vitro system. Activation required TAFIls and was enhanced by the
general transcription factor TFIIA. The TFIID-TFIIA complex was shown to be critical
for activated transcription and the concomitant presence of TFIID, TFIIA, activator and
topoisomerase I was required for maximal activation. An electrophoretic mobility shift
assay (EMSA) demonstrated that activator dramatically increased the rate and extent of
formation of the TFIID-TFIIA complex in the presence of topoisomerase I. DNase I
footprinting confirmed the EMSA findings. A camptothecin mediated cleavage assay
was used to demonstrate the presence of topoisomerase I in the initiation complex and its
interaction with TFIID.
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Introduction
Initiation of transcription by RNA polymerase II is a multi-step process involving
six defined activities termed the general transcription factors (GTFs) and the polymerase
(PollI). Each of the GTFs except TFIIB is a multimeric assembly of polypeptides thus
bringing the number of proteins required to initiate transcription on a typical promoter to
approximately forty. The GTFs: TFIID, TFIIB, TFIIE, TFIIF, TFIIH, and PoIlI assemble
on the promoter in an ordered fashion (Buratowski, 1994). This assembly is nucleated by
TFIID (Samuels et al., 1982; Davison et al., 1983) which binds the TATA box and can
make further contacts with the promoter region as far away as +40 from the site of
initiation (Sawadogo and Roeder, 1985; Zhou et al., 1992). The 43kD TATA binding
protein (TBP) subunit of TFIID contacts the DNA in the minor groove at the TATA box
and bends it (Nikolov et al., 1992). The remaining subunits of TFIID are termed TAFs
(TBP Associated Factors) (Dynlacht et al., 1991). One of these TAFs, of molecular
weight 150 kD, contacts the DNA downstream of the TATA box and is responsible for
the extended footprint of TFIID on the promoter (Verrijzer et al., 1994).
The inability of sequence-specific transcriptional activators to increase the rate of
initiation in purified in vitro reactions (Meisterernst et al., 1991), and the ability of TBP
to support the basal reaction but not activation (Dynlacht et al., 1991), led to the
discovery of coactivating factors necessary for activation but not required for the
unstimulated or basal reaction. These coactivators fall broadly into two categories: 1)
members of the TAFs, which are tightly associated with the TBP, and 2) soluble factors
not complexed with any of the GTFs. Both have been reported to be required for
activation in defined, reconstituted reactions, and neither can obviate the requirement for
the other. The soluble coactivators defined by biochemistry to date include PC-4 (Ge and
Roeder, 1994; Kretzschmar et al., 1994) topoisomerase I (Kretzschmar et al., 1993;
Merino et al., 1993), HMG-1/2 (Shykind et al., 1995) and HMG-17 (Paranjape et al.,
1995) Less well characterized fractions with coactivator activity include PC-2
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(Kretzschmar et al., 1994) and ACF (Merino et al., 1993). The factor TFIIA is
dispensable for the basal reaction in purified systems while in cruder in vitro reactions
TFIIA derepresses transcription. TFIIA has been shown to be indispensable for
activation both in crude extracts and in highly defined systems (Ma et al., 1993; Ozer et
al., 1994; Shykind et al., 1995) and it contributes to activation in vivo (Sun et al., 1994).
Thus TFIIA acts as a coactivator in addition to its role counteracting basal repression. In
yeast, a large complex containing PolII, SRB proteins, and many other polypeptides can
mediate activation (Kim et al., 1994; Koleske and Young, 1994). This holoenzyme
complex contains coactivating activities tightly associated with the polymerase that
potentiate functional interaction with activator. A genetic screen has identified a set of
proteins that boost stimulation by acidic activators (Berger et al., 1992)
Some of the general transcription factors have been reported to interact with the
activation domains of sequence specific activators including TBP (Stringer et al., 1990),
TFIIB (Lin et al., 1991; Roberts et al., 1993) and TFIIH (Xiao et al., 1994). Functional
studies have identified the TFIIB bind step as a target of activator function (Lin and
Green, 1991), with a proposed conformational change in the factor (Roberts and Green,
1994). The TFIID-TFIIA binding stage has also been shown to be altered during
activation (Wang et al., 1992; White et al., 1992; Lieberman and Berk, 1994; Shykind et
al., 1995). Such interactions are presumed to potentiate transcription either directly, by
increasing the rate of recruitment of the particular factor, or indirectly, by enhancing
subsequent steps in the process. The ability of activation domains to interact with several
of the GTFs has been proposed to account for the synergy observed in stimulation by
multiple activators. In the absence of coactivators, activator-GTF interactions alone are
not sufficient for activation, as in vitro reactions containing highly purified factors,
shown to bind to activation domains, do not support stimulation. Functional and physical
interactions between activators and coactivators have been defined. The variety of
activation domains has been proposed to be functionally translated by the assorted TAFs
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of the TFIID complex (Tjian and Maniatis, 1994) Indeed TAF-activator interactions have
been demonstrated: TAF 110 was shown to bind to the glutamine rich activation domains
of Spl (Hoey et al., 1993; Gill et al., 1994), and TAF 40 was shown to bind to the C-
terminal activation domain of VP16 (Goodrich et al., 1993). Additionally, multiple
activator-TAF interactions have been shown to generate synergy in activation (Sauer et
al., 1995). The soluble coactivator PC-4 was recently cloned and shown to interact with
several activation domains in addition to binding to the TFIID-TFIIA complex (Ge and
Roeder, 1994; Kretzschmar et al., 1994). In yeast the putative coactivator ADA-2 was
shown to bind to the activation domain of VPl6 (Silverman et al., 1994).
Topoisomerase I was originally proposed to function in transcription by relieving
the torsional stress believed to accompany elongation (Wang, 1985) A link between
DNA topology and transcriptional regulation was suggested by early studies in
Escherichia coli and from theoretical considerations (reviewed by Wang, 1992)
Subsequently, topoisomerase I has been shown to be associated with actively transcribed
regions of chromatin (Weisbrod, 1982; Fleischmann et al., 1984; Gilmour et al., 1986).
Inhibitor studies have demonstrated both physical functional involvement of
topoisomerase I with actively transcribed genes (Stewart and Schutz, 1987; Zhang et al.,
1988; Bendixen et al., 1990; Stewart et al., 1990). Antibody to topoisomerase I has been
shown to interfere with elongation in vivo (Egyhazi and Durban, 1987). Topoisomerase I
has also been localized to non-transcribed regions of chromatin associated with DNase I
hypersensitive regions (Bonven et al., 1985; Stewart and Schutz, 1987). Recently
topoisomerase I was identified biochemically as a coactivator (Kretzschmar et al., 1993;
Merino et al., 1993). The mechanism of coactivation is likely to involve a pre-elongation
step as a catalytically inactive mutant of the enzyme is able to potentiate activation.
Further, topoisomerase I was shown to coimmunoprecipitate with the TFIID complex and
can bind to TBP (Merino et al., 1993). Thus this abundant nuclear enzyme may function
at two stages of transcription.
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In this paper, the mechanism of stimulation of transcription potentiated by the
coactivator DNA topoisomerase I is examined. We demonstrate its ability to potentiate
activation in a highly defined in vitro system and show that it exerts its effect at the
TFIID-TFIIA binding step. Maximal activation requires the concomitant participation of
topoisomerase I, activator, TFIID and TFIIA on the promoter. Using a gel shift assay, the
activation step is shown to be accompanied by a dramatic increase in the formation of the
TFIID-TFIIA complex with activator and coactivator. TFIIA and TAFIIs are required
both for transcriptional activation and for enhancement of initiation complex formation.
A catalytically inactive topoisomerase I mutant that has been shown to coactivate,
similarly stimulates TFIID-TFIIA complex formation. DNase I footprint data confirms
the increase in TFIID-TFIIA complex formation in activation. Camptothecin mediated
cleavage of the template by topoisomerase I shows that TFIID recruits the coactivator to
the promoter at several sites, thus placing the coactivating topoisomerase I in the TFIID-
TFIIA-activator complex.
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Results
DNA Topoisomerase I coactivates transcription in highly purified Pol II system
Purified human DNA topoisomerase I was titrated into in vitro transcription
reactions of highly defined factors. This in vitro system is unable to support activation in
the absence of soluble coactivators (Shykind et al., 1995; Appendix C). As is shown in
Figure lA, lanes 1-6, in the absence of activator, topoisomerase I increased and then
repressed basal transcription from the two supercoiled, major late templates. This stands
in contrast to previous investigations where topoisomerase I was reported to function
solely as a repressor in the basal reaction (Merino et al., 1993; Kretzschmar et al., 1993).
In the presence of the activator Gal4-VP16 (Figure lA, lanes 7-12), topoisomerase I
potently stimulated transcription off of the major late promoter fused to three Gal4
binding sites (ML-3G). At completely repressing levels of topoisomerase I, activator
maintained basal levels of transcription (compare lanes 6, 7, and 12). The two
transcriptional activities of topoisomerase I, basal enhancing and coactivating, show
sharp titration curves. Maximal activity is seen within half a log of titration and
repression of transcription upon titration up of one-half log. The transcriptional activities
of topoisomerase I seen in the basal and activated reactions are typical of the behavior of
defined coactivators such as PC-4 and HMG-2 in this transcription system (Shykind et
al., 1995; Appendix C), wherein basal levels of transcription are boosted and then
repressed upon titration of the coactivator.
Topoisomerase I was next tested on linear transcription templates (Figure IB).
Dissimilarly to its effect on supercoiled template, in the absence of activator,
topoisomerase I differentially boosted and then repressed basal transcription from the two
major late promoters. As seen in lanes 1-6, the longer (390nt) transcript (ML-3G) was
repressed at a lower concentration of topoisomerase I than was the shorter (180nt)
transcript (ML). In the presence of activator, transcription from the ML-3G template was
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activated upon titration of topoisomerase I (lanes 7-12). The differential effect
topoisomerase I exerts on linear template is examined in Appendix B.
To examine the requirement for TAFfls (Pol II TBP Associated Factors) in the
modulation of transcription by topoisomerase I, recombinant TBP was used instead of
holoTFIID in the in vitro reactions. As seen in Figure 1 C, lanes 1-6, in contrast to the
TFIID driven reaction, no boost to basal transcription occurred upon titration of
topoisomerase I. However, repression of transcription was observed at the highest levels
of topoisomerase I addition. In the presence of activator (Figure IC, lanes 7-12),
stimulated levels of transcript were not generated (in agreement with Kretzschmar et al.
1993), although very slight derepression was seen at the highest levels of topoisomerase I
addition. Thus the TAFIIs are required for both basal enhancement and coactivation.
TFIIA requirement
Several studies have demonstrated the requirement of TFIIA for activation both in
vitro and in vivo (Ma et al., 1993; Ozer et al., 1994; Sun et al., 1994; Shykind et al.,
1995; Stargell and Struhl, 1995) To examine whether TFIIA participates in activation
coactivated by topoisomerase I, TFIIA was titrated into transcription reactions in the
presence of activator and varying amounts of topoisomerase I (Figure 2). In the absence
of TFIIA, topoisomerase I supported slight activation by Gal4-VP16 (lanes 1-4).
However, the degree of activation upon titration of topoisomerase I increased
dramatically with increasing amounts of TFIIA (compare lanes 2 and 3 with 6 and 7, 10
and 11, 14 and 15). TFIIA also boosted the enhancement of basal transcription seen in
Figures lA and B by topoisomerase I (compare ML transcript at various TFIIA levels).
Thus TFIIA plays a critical role in stimulation of transcription coactivated by
topoisomerase I.
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Temporal parameters for activation
The gross temporal requirements for the formation of the activated initiation
complex were examined by an order-of-addition transcription assay wherein
topoisomerase I, activator, and the GTFs were incubated in different combinations and
added in different orders to template (Figure 3A). A one hour first incubation with
factor(s) and templates was followed by a second and final one hour incubation wherein
factor(s) and NTPs were added. As seen in Figure 3A, in the absence of both activator
and coactivator, no significant activation was observed (lanes 1-8), although some
modulation of the basal reaction was seen. In lane three, where topoisomerase I was
added to template first, and GTFs were subsequently added, some repression of
transcription occurred. However, when topoisomerase I and GTFs were coincubated with
template in the first incubation, some boost to basal was seen (lane 7). As expected,
strong activation was generated when all three components (activator, topoisomerase 1,
and GTFs) were added together to template either in the first (lane 9), or in the second
(lane 10) incubation. If topoisomerase I and the GTFs were added together in the first
incubation to template, followed by activator in the second incubation, less stimulation
occurred (lane 11). Addition of activator and GTFs followed by topoisomerase I
generated near basal levels of transcription (lane 12). When topoisomerase I was
incubated with template alone, followed by activator and GTFs, little activation occurred
(lane 13). The only factor that could bind to the templates first and still yield activation
was the activator (lane 14). Addition of activator and topoisomerase I in the first
incubation, followed by GTFs (lane 15), or GTFs followed by activator and
topoisomerase I (lane 16) yielded little and no activation respectively. Thus the activator,
coactivator, and some component(s) of the GTFs are required to be present with the
template at the same time, for activation to occur.
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Defining the stage of activation
The stage of initiation altered by topoisomerase I in the presence of the activator
Gal4-VP16 was further investigated by order-of-addition experiments wherein
topoisomerase I and activator were added at distinct points in the initiation of
transcription (Figure 3B). Complexes were formed on templates in the absence or
presence of activator and coactivator in the first incubation, or were formed alone and
then followed by activator and coactivator during the second incubation. Nucleotides and
GTFs required for the reaction were added in the second incubation step. Figure 3B lanes
1-3 show that, in agreement with figure 3A, the stimulation of transcription was higher
when activator and coactivator were added in the second incubation along with the GTFs
than when added first to the template. No difference in activation was observed when
TFIID was preincubated with the templates either alone or in the presence of
topoisomerase I and Gal4-VP16 (lanes 5 and 6). At the TFIID-TFIIA binding stage of
initiation, activation was more pronounced when IID, IIA, activator and coactivator were
coincubated (lane 8) than when the IID-IIA binding step was followed by addition of
activator and coactivator (lane 9). The subsequent stages of initiation showed the
requirement for the presence of activator and coactivator in the first incubation step,
where TFIID and TFIIA and GTFs were committing to the template, for maximal
activation. At the stage of formation of the TFIID-A-B-F-pol complex (lanes 16-18),
very little transcription over the basal level was observed when activator and coactivator
were added in the second incubation, after the complex had committed (compare lanes 16
and 18). Thus the TFIID-TFIIA binding step of initiation is the first stage of activation
altered by the presence of activator and topoisomerase I.
The formation of the activated TFIID-TFIIA complex was further functionally
dissected by order-of-addition experiment to determine the effect on stimulation of
temporally separating the addition of activator and coactivator. In Figure 3C, TFIID and
TFIIA were incubated with template in the first incubation. Topoisomerase I was titrated
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into the reaction either before, in the first incubation, or in the second incubation; and
activator was similarly added before or after the TFIID-TFIIA binding step.
Interestingly, maximal activation was observed when TFIID, TFIIA, topoisomerase I and
Gal4-VP16 were jointly incubated with template (lanes 4-6). Less activation occurred
when topoisomerase I was included in the first incubation and activator was added in the
second incubation (lanes 1-3). When activator was included in the first incubation and
topoisomerase I in the second (lanes 10-12), or when activator and coactivator were
added after the IID-IIA binding step (lanes 7-9) little activation occurred. Thus activator
and coactivator must be present together at the TFIID-TFIIA binding stage for maximal
activation, and temporal separation of the addition of activator and coactivator at this
stage decreases stimulation.
Topoisomerase I facilitates formation of the TFIID-TFIIA complex
The definition of the TFIID-TFIIA binding stage as the critical step in activation
with topoisomerase I led us to examine the possibility that this early initiation complex
may interact with the coactivator on the promoter. HoloTFIID binding to the TATA box
has been demonstrated by electrophoretic mobility shift assay (Zhou et al., 1992).. We
therefore used an agarose electrophoretic mobility shift assay (EMSA) to probe the early
events in activation (Figure 4A). DNA fragment containing the major late promoter
fused to three Gal4 binding sites was end-labeled with 32P radionucleotide and used as a
gel shift probe. The titration of topoisomerase I alone led to the shifting of probe into the
well at the highest titration point (lane 4). TFIID on its own formed barely detectable
amounts of complex (lane 5); topoisomerase I titration did not enhance this formation
(lanes 6-8). The addition of TFIIA with TFIID led to the generation of detectable levels
of TFIID-TFIIA complex (lane 9), which was stimulated by the addition of
topoisomerase I (lanes 10-11). The highest titration point of topoisomerase I either
inhibited complex formation or shifted all the complex into the well (lane 12).
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The interaction of topoisomerase I and the activator with the initiation complex was
similarly analyzed by mobility shift assay (Figure 4B). In the presence of TFIIA,
topoisomerase I facilitated the binding of TFIID (lanes 10-12) as was observed in Figure
4A. Strikingly, the addition of activator to this binding reaction greatly enhanced the
formation of complex (lanes 13-15). Activator on its own shifted the probe slightly and
was unaffected by topoisomerase I titration (lanes 1-3). To test for the requirement of
TAFIIs in this stimulation of complex formation, TBP was used in place of TFIID. As
shown in Figure 4C, the TBP complex alone was not stable in this gel system nor was it
stabilized by topoisomerase I in the absence (lanes 1-3) or presence (lanes 4-6) of
activator. When TFIIA was included in the binding reaction, a TBP-TFIIA complex
readily formed (lane 7). This complex was not affected by increasing amounts of
topoisomerase I in the absence (lanes 7-9) or presence (lanes 10-12) of activator. Thus
TAFIIs were required both for the stimulation of TFIID-TFIIA complex formation by
topoisomerase I and for the super-stimulation of the complex when activator and
topoisomerase I were both present.
Kinetics of complex formation
The formation of TFIID-TFIIA complex with activator and coactivator was
examined kinetically (Figure 5A). TFIID, TFIIA, and topoisomerase I were mixed
together on ice and added to probe, in the presence and absence of activator, and
incubated at 300 C for varying amounts of time prior to EMSA analysis. In the absence of
activator (lanes 1-5), some complex was detected after one minute of incubation (lane 1),
and was still seen forming after one hour of incubation (lane 5). Strikingly, the addition
of Gal4-VP16 (lanes 6-10) increased the rate of formation of the complex, such that the
full level of complex formation had been reached after one minute of incubation (lane 6).
The slight elevation of complex formed after one minute compared to that formed after
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sixty minutes may be due to the requirement of topoisomerase I and TFIID to interact
with each other before they come in contact with the template (see Discussion).
The dissociation of the TFIID-TFIIA-topoisomerase I complex with and without
activator was examined by EMSA (Figure 5B). Complexes were formed for thirty
minutes prior to addition of inhibitory amounts of competitor dIdC and further
incubation. In the absence of activator (lanes 1-6), little complex dissociated over the
four hour course of the experiment. In fact, more complex was seen at the end of the time
course (lane 6) In the presence of activator (lanes 6-12), no dissociation of complex was
observed. Further, more complex was present at the last time point (four hours) than at
the first, indicating an increased stabilization of the complex over time.
TFIIA requirement
The critical role of TFIIA in topoisomerase I coactivation shown by transcription
was examined by EMSA (Figure 6). TFIIA was titrated over three logs in a twenty
minute binding reaction with factors and the major late probe. In the presence of TFIID
alone, (lanes 1-4), no effect was seen on complex formation upon TFIIA titration. When
both TFIID and topoisomerase I were present, TFIIA stimulated complex formation to a
modest level (lanes 5-8). The addition of activator to TFIID and topoisomerase I
generated no complex (lane 9). However, titration of TFIIA to this reaction dramatically
increased complex formation (lanes 10-12). Consistent with the phenomenology seen in
the transcription reactions, TFIIA stimulated the rapid formation of a TFIID-TFIIA-
topoisomerase I complex in the presence of activator.
TFIID, TFIIA, topoisomerase I and activator required concomitantly
Order-of-addition experiments showed that activation mediated by topoisomerase
I occurred at the TFIID-TFIIA binding stage (Figure 3B) and that maximal stimulation
required concomitant incubation of TFIID, TFIIA, activator and topoisomerase I with the
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template (Figure 3C). The formation of the TFIID-TFIIA complex with topoisomerase I
and activator was similarly dissected by order-of-addition EMSA to determine the
temporal order of factor addition critical for enhanced assembly of this initiation complex
(Figure 7). Various combinations of the factors involved were added to probe in the first
incubation, or added in the second incubation, and subsequently analyzed by EMSA. The
incubation of TFIID without (lanes 1-3) or with (lanes 4-6) TFIIA produced little
complex when topoisomerase I was included in the second incubation, without respect to
the presence of activator or the subsequent addition of TFIIA. TFIID coincubated with
topoisomerase I on the probe (lanes 7-9) similarly produced little complex when TFIIA
was added in the second incubation. Again without respect to activator. However, when
all four factors were present in the first incubation with probe, dramatic stimulation of
complex formation was observed (lane 11). The inclusion of topoisomerase I with probe
in the first incubation followed by TFIID and TFIIA produced little complex with or
without activator (lanes 13-15). Thus the enhanced rate of TFIID-TFIIA complex
formation by topoisomerase I and activator, mirrored the transcription order-of-addition
experiment, and depended on the concomitant incubation of all four factors with the
probe. This suggests that a highly specific interaction of the factors with the DNA is
required for enhanced complex formation (see Discussion).
Mutant topoisomerase I coactivates and stimulates complex formation
A catalytically inactive point mutant topoisomerase I has been described that
retains its binding properties but does not relax supercoiled DNA (Madden and
Champoux, 1992) This protein has been reported to support activation in vitro in a less
well defined transcription system (Merino et al., 1993).. To examine topoisomerase I
functional requirements for coactivation and enhancement of TFIID-TFIIA complex
formation, the mutant enzyme was tested in transcription and in EMSA. In Figure 8,
mutant topoisomerase I was titrated into transcription reactions in the absence (lanes 1-6),
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and the presence (lanes 7-12) of activator. Similar to the wild-type protein, the mutant
boosted and then repressed basal transcription (lanes 1-6). However, in the presence of
activator, the mutant potentiated stimulation of transcription on the ML-3G template, but
the majority of transcripts failed to elongate to the end of the 390nt G-less cassette (lanes
7-12). This suggests that the binding properties of topoisomerase I are sufficient for
coactivation while the relaxing activity is required for full-length elongation (see
Discussion).
Similarly to the wild-type protein, the mutant topoisomerase I enhanced formation
of the TFIID-TFIIA complex in the presence of activator (Figure 9). In the absence of
Gal4-VP16 (lanes 1-4), little TFIID-TFIIA complex was generated during the twenty
minute binding reaction upon mutant topoisomerase I titration. However, in the presence
of activator (lanes 5-8), titration of the mutant stimulated and then repressed TFIID-
TFIIA complex formation. Thus the EMSA analysis mirrored the transcription assay for
the mutant protein.
Footprint of activated TFIID-TFIIA complex
DNase I footprinting was used to examine the enhancement of TFIID-TFIIA
complex formation by activator and topoisomerase I (Figure 10) Under conditions
identical to those used in the gel shift reactions, complexes were formed for thirty
minutes and then subject to DNase I cleavage. Topoisomerase I was included in the even
numbered lanes and activator was added in alternate pairs of lanes. On its own,
topoisomerase I did not protect sequences in the promoter region (lane 2). Upon addition
of saturating amounts of Gal4-VP 16, the three Gal4 sites became protected and remained
unaltered by the addition of topoisomerase I (lanes 3 and 4). No protection of the TATA
region was seen upon addition of TFIID in the absence or presence of activator and
topoisomerase I (lanes 5-8). Slight protection of the TATA box was observed when
TFIID, TFIIA and topoisomerase I were incubated with the probe (lane 10), and strong
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protection of the TATA region, a hypersensitive site at -43, and an extended footprint of
protection out to approximately +37 was seen when TFIID, TFIIA, topoisomerase I and
activator were all included in the reaction (lane 12). Thus DNase I footprinting confirms
the results of the EMSA analysis wherein formation of the TFIID-TFIIA complex is
strongly stimulated by topoisomerase I in the presence of activator. The presence of
topoisomerase I in the complex was not detected by this footprinting method.
Camptothecin mediated self-footprinting of topoisomerase I
To determine whether topoisomerase I was present in the initiation complex on
the promoter, a topoisomerase I nicking assay was used in which the covalent
topoisomerase I-3'-DNA intermediate was trapped by the drug camptothecin, leaving a
nick in the DNA at the site of the chemistry (Hsiang et al., 1985). This assay takes
advantage of the ability of topoisomerase I to enzymatically attack superhelically
unstressed DNA. The radiolabeled gel-shift probe was used to analyze the site(s) of
topoisomerase I binding (binding plus nicking). Complexes were formed under
footprinting conditions in the presence of 25tM camptothecin. Reactions were
subsequently processed with proteinase K and analyzed by denaturing polyacrylamide gel
electrophoresis (see Materials and Methods). As seen in Figure 11, lane 12,
topoisomerase I on its own strongly bound to a site in the promoter at -80, and to four
sites with less affinity. Additionally, it bound several sites with low affinity. The
cleavage sites are A-T rich, as has been reported (Busk et al., 1987). Upon addition of
activator (lane 11), the prominent cleavage at -80 was inhibited, as were the cleavages
downstream of it. The inhibition of the -80 cut is not surprising as this site lies in the
region protected by Gal4-VP16 in DNase I footprinting (Figure 10). The disappearance
of downstream cleavages almost ninety base pairs away is remarkable and could suggest
that the topoisomerase I binds cooperatively in this region. Simple binding to the Gal4
sites similarly blocked these downstream cuts as demonstrated by Gal4 1-94 (data not
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shown). The addition of TFIID to the binding reaction (lane 10) did not substantially
alter the topoisomerase I self-footprint. However, in the presence of Gal4-VP16, which
blocked the cleavage, TFIID brought many of the cleavage sites back (lane 9). TBP did
not have this effect (lane 7), demonstrating the requirement for TAFIIs in this
recruitment. Addition of five-fold less topoisomerase I generated no cleavage of the
probe (lane 6). However, cleavage by topoisomerase did occur when TFIID was added
(lane 4). Addition of activator and TFIID (lane 3) eliminated some of the sites (-80, -45,
-40) but three upstream cuts remained. Again the TAFIls were shown to be required for
this recruitment as TBP did not generate this effect (lanes 1 and 2). Thus topoisomerase I
can bind to the ML promoter, interacting with TFIID dependent on its TAFIIs. A
summary of both the footprinting and camptothecin nicking data is shown in Figure 12.
The topoisomerase binding sites identified by self-footprinting lie in regions of the
promoter protected by both TFIID and Gal4-VP16. Thus topoisomerase I was able to
contact the DNA in these regions although DNase I was not. The multiple sites bound by
topoisomerase I in the presence of TFIID and activator coupled with the ability of TFIID
to recruit topoisomerase I to some of those sites suggests that a large multi-component
complex is forming on the promoter that may be contacting TFIID and the DNA at
several points. The ability of topoisomerase I molecules bound far upstream to interact
with TFIID bound at the TATA box, further suggests that the DNA of the promoter
region may be bending.
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Discussion
We have identified the TFIID-TFIIA stage of initiation of transcription as the
critical step in activation potentiated by topoisomerase I. Maximal activation is
dependent on the concomitant participation of TFIID, TFIIA, topoisomerase I and
activator on the promoter. Activation is dependent on the TAFII coactivators and is
strongly influenced by TFIIA concentration. The activation step correlates with a
dramatic increase in the rate and extent of formation of the TFIID-TFIIA complex as
shown both by agarose EMSA and by DNAse I footprinting. Enhanced TFIID-TFIIA
complex formation is dependent on TAFIIs and TFIIA and the concomitant reaction of all
four early complex factors: TFIID, TFIIA, topoisomerase I and activator. A catalytically
inactive point mutant of topoisomerase I that stimulates increased initiation
correspondingly enhances TFIID-TFIIA complex formation as demonstrated by EMSA.
Utilizing the ability of camptothecin to freeze the topoisomerase I-nicked DNA
intermediate at the site of relaxation, we have shown that the coactivator is present at the
promoter and is stabilized by the TFIID complex, dependent on TAFIIsIjs. Thus
topoisomerase I enhances the recruitment of TFIID with TFIIA and activator and is likely
acting through the TAFIIs at the site of initiation complex formation during the activating
step.
The order-of-addition experiments presented here, both in transcription and
EMSA, suggest that the action of activator and coactivator cannot be temporally
separated and still maintain maximal activation. Additionally, TFIID and TFIIA cannot
first be incubated with the promoter, either with activator or coactivator, if maximal
activation is to occur. Therefore, if activation at the TFIID-TFIIA step were due to
simple recruitment, then it might be expected that order of addition would be irrelevant as
the TFIID and TFIIA would remain in solution unbound, until recruited by activator in
the context of the coactivator. This produces three possible scenarios. The TFIID-TFIIA
complex could bind DNA tightly with little specificity such that without the influence of
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the activator and coactivator directing it to the initiation site, it is soaked up by template
with very little bound at the promoter. This is unlikely as no complex was observed by
EMSA in the absence of activator and coactivator. The second possibility is that TFIID-
TFIIA does accurately bind to the promoter, but in the absence of activator and
coactivator a stable, low activity complex is formed. Experimental evidence from the
study of coactivation by HMG proteins suggested that once bound, TFIID is not
amenable to activation (Shykind et al., 1995). Analysis of open complex formation by
permanganate footprinting, which detected enhanced formation of open complex at the
TFIID-TFIIA activator binding step (using crude fractions), demonstrated a similar
refractivity to activation if TFIID bound alone (Wang et al., 1992). Thus it is possible
that concomitant participation of all four factors produces a structural change in the
initiation complex required for the activated state. The final possibility is that the only
difference between basal and activated reactions is a simple increase in the amount of
TFIID present but that its recruitment requires a precisely choreographed, stereospecific
complex at the promoter involving all four identified participants: TFIID, TFIIA.,
activator, and topoisomerase I. This possibility is unlikely as the degree of activation
with topoisomerase I does not diminish with increasing amounts of TFIID (data not
shown). Further, the degree of activation is not strictly dependent on the time of
formation of the TFIID-TFIIA complex (data not shown).
The TFIID-TFIIA complex as been reported to be an early, critical stage of
activation (Wang et al., 1992; Lieberman and Berk, 1994; Shykind et al., 1995; Kaiser et
al., 1995), and TFIIA has been shown to be required for activation (Ma et al., 1993; Ozer
et al., 1994; Sun et al., 1994). Our results are consistent with and extend the findings of
Wang et al (1992) who observed a decrease in the lag time of open complex formation, as
assayed by permanganate footprinting, when crude TFIID, TFIIA, and Gal4-AH were
coincubated on the adenovirus E4 promoter. It is likely, in fact, that the crude TFIID
fraction used by Wang et al. contained topoisomerase I, as TFIID and topoisomerase I
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coimmunoprecipitate from crude fractions (Merino et al., 1993). Lieberman and Berk
(1994) demonstrated that the formation of the TFIID-TFIIA complex on the E4 promoter
was greatly enhanced by the Zta activator from seven upstream Zta-sites. However, this
effect was not sufficient for activation in the absence of the USA coactivator fraction
described by Meisterernst et al. (1991). Here we have demonstrated a similar
enhancement of TFIID-TFIIA complex formation. However, this enhancement was
completely dependent on the presence of topoisomerase I , which alone coactivated
strong stimulation in our in vitro system. We saw little effect on TFIID-TFIIA complex
formation by activator alone by transcription assay, EMSA, or footprint assay.
Additionally, unlike Lieberman and Berk, we saw no increase in the stability of the
TFIID-TFIIA complex in the presence of activator and coactivator. These differences
may be due to differences in the core promoter, adeno E4 versus major late, the number
activator sites, seven versus three, and the type of activator present. Similar to the
phenomenology Lieberman and Berk, enhancement of this early initiation complex
depended on TAFIs, TFIIA, and was characterized by an increase in the rate and extent
of complex formation.
It is possible that no single activator-GTF or activator-coactivator interaction can
explain the mechanism of activation of pol II transcription. Individual binding steps may
become limiting in the context of different core promoter elements (Das et al., 1995) or in
chromatin. Activators may have different activities in the presence of different
coactivators (Lehming et al., 1994), and different coactivators may require different core
promoter set ups (Shykind et al., 1995). Additionally, the process is dynamic, and must
be viewed as a tightly choreographed series of steps such that individual interactions may
only become functionally relevant in specific geometries. The search for defining protein-
protein interactions therefore may be of limited heuristic value. Increasingly, factors that
effect transcription are being identified that interact not only with the protein components
of the reaction but also bind and often alter the DNA of the promoter region. Such
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factors include the non-histone chromosomal proteins of the three HMG families
(Thanos and Maniatis, 1992; Paranjape et al., 1995; Shykind et al., 1995), HMG box
containing factors such as UBF and LEF-1 (Jantzen et al., 1990; Giese et al., 1992), and
proteins with DNA binding activity like PC-4 (Ge and Roeder, 1994; Kretzschmar et al.,
1994). Thus activators of certain classes may require specific associated coactivators that
impart a critical structure. Some activators like LEF-1 appear to contain both structure
generating and activation domains.
Topoisomerase I binds to DNA, preferring irregular structures such as nodes
where DNA strands cross over each other (Zechiedrich and Osheroff, 1990). Further,
bent DNA has been reported to stabilize topoisomerase I binding (Krogh et al., 1991).
Merino and colleagues reported the ability of topoisomerase I to associate with the TFIID
complex, eluting in moderate salt concentrations (Merino et al., 1993). In this work,
camptothecin mediated cleavage has demonstrated the ability of topoisomerase I to bind
to the promoter, in the region of the promoter protected by TFIID. Additionally, TFIID
stabilizes topoisomerase, via its TAFIIs at several sites in the promoter region. Thus a
model of early activation can be formulated wherein topoisomerase I mediates a protein-
DNA structure with TFIID such that in the presence of activator and TFIIA, an activated
initiation complex is generated. This activation event is characterized by an increase in
the rate and extent of formation of the TFIID-TFIIA-activator-coactivator complex. The
manifestation of this activation may be the increased recruitment of TFIIB, TFIIF, and
RNA polymerase II seen upon activation by Choy and Green (1993). Alternatively, this
early activated complex could be a high affinity platform for a holopolymerase complex
(Kim et al., 1994; Koleske and Young, 1994)
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Figure IA
Topoisomerase I potentiates activation by Gal4-VP16 on supercoiled Major Late
promoters. ML transcript (180nt) was generated by 25ng supercoiled MLP basal control
promoter. ML-3G transcript (390nt) was generated by 25ng supercoiled MLP with three
Gal4 binding sites fused upstream. Lanes 1-6: titration of topoisomerase I over one log
(with 200ng topoisomerase I maximum) in the absence of activator. Lanes 7-12: titration
of topoisomerase I over one log in the presence of the synthetic activator Gal4-VP16.
Transcription reactions were analyzed, after purification, on 10% polyacrylamide gels
with 8M urea, and gels were subject to autoradiography.
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Figure lB
Topoisomerase I potentiates activation by Gal4-VPl6 on linear Major Late promoters.
ML transcript (180nt) was generated by 25ng linear MLP basal control promoter. ML-
3G transcript (390nt) was generated by 25ng linear MLP with three Gal4 binding sites
fused upstream. Lanes 1-6: titration of topoisomerase I over one log (with 200ng
topoisomerase I maximum) in the absence of activator. Lanes 7-12: titration of
topoisomerase I over one log in the presence of the synthetic activator Gal4-VP16.
Transcription reactions were analyzed, after purification, on 10% polyacrylamide gels
with 8M urea, and subject to autoradiography.
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Figure IC
Topoisomerase I does not obviate the requirement for TAHFIs in activation by Gal4-VP16
on super-coiled Major Late promoters. ML transcript (180nt) was generated by 25ng
supercoiled MLP basal control promoter. ML-3G transcript (390nt) was generated by
25ng supercoiled MLP with three Gal4 binding sites fused upstream. Lanes 1-6: titration
of topoisomerase I over one log (with 200ng topoisomerase I maximum) in the absence
of activator. Lanes 7-12: titration of topoisomerase I over one log in the presence of the
synthetic activator Gal4-VP16. Reactions contained 10ng recombinant human TBP.
Transcription reactions were analyzed, after purification, on 10% polyacrylamide gels
with 8M urea, and subject to autoradiography.
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Figure 2
TFIIA boosts activation by Gal4-VP16 potentiated by topoisomerase I. ML transcript
(180nt) was generated by 25ng supercoiled MLP basal control promoter. ML-3G
transcript (390nt) was generated by 25ng supercoiled MLP with three Gal4 binding sites
fused upstream. TFIIA was titrated over three logs in the presence of activator.
Topoisomerase I was titrated over one log at each TFIIA concentration. Transcription
reactions were analyzed, after purification, on 10% polyacrylamide gels with 8M urea,
and subject to autoradiography.
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Figure 3A
Order-of-addition transcription demonstrates temporal requirements for activation.
During first incubation of 60 minutes at 300C, activator and or topoisomerase I and or
GTFs were incubated with 25ng of each super-coiled template: basal control (ML) or
containing activator binding sites (ML-3G). In the second 60 minute incubation,
transcription factors as indicated and NTPs were added under transcription conditions.
Transcription reactions were analyzed, after purification, on 10% polyacrylamide gels
with 8M urea, and subject to autoradiography.
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Figure 3B
Order-of-addition transcription defines the TFIID-TFIIA step of initiation as critical in
activation potentiated by topoisomerase I. Gal4-VP16 and topoisomerase I were added
together before or after different stages of initiation complex formation, or were omitted.
ML transcript (180nt) was generated by 25ng supercoiled MLP basal control promoter.
ML-3G transcript (390nt) was generated by 25ng supercoiled MLP with three Gal4
binding sites fused upstream. Transcription reactions were analyzed, after purification,
on 10% polyacrylamide gels with 8M urea, and subject to autoradiography.
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Figure 3C
Maximal activation requires the presence of activator and coactivator during TFIID-
TFIIA complex formation. Order-of-addition transcription performed as in figure 3A.
Gal4VP16 and two concentrations of topoisomerase I were added before or after
formation of the TFIID-TFIIA complex. NTPs and remaining GTFs were added in the
second 60 minute incubation. ML transcript (180nt) was generated by 25ng supercoiled
MLP basal control promoter. ML-3G transcript (390nt) was generated by 25ng
supercoiled MLP with three Gal4 binding sites fused upstream. Transcription reactions
were analyzed, after purification, on 10% polyacrylamide gels with 8M urea, and subject
to autoradiography.
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Figure 4A
Topoisomerase I enhances formation of the TFIID-TFIIA complex. 1.5% agarose gel
shifts performed with 32 P-labeled ML probe with three Gal4 binding sites in the presence
of 100ng competitor dGdC. Topoisomerase I was titrated (0, 0.1, 0.3, 1.0/l), alone (lanes
1-4), with holoTFIID (lanes 5-8), and with holoTHID (IID) and TFIIA (IIA) (lanes 9-12),
for one hour at 30 0 C and then subject to agarose EMSA. "D-A" is the TFIID-TFIIA
complex. Gels were dried down and subject to autoradiography.
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Figure 4B
Activator enhances formation of the THFIID-TFIIA complex in the presence of
topoisomerase I. 1.5% agarose gel shifts performed with 32P-labeled ML probe with
three Gal4 binding sites in the presence of 100ng competitor dGdC. Topoisomerase I
was titrated (0, 0.1, 0.3pl) in the presence of combinations of Gal4-VP16 (G), TFIIA, and
holoTFIID. Reactions were incubated for 1 hour at 300C and then analyzed by agarose
EMSA. Gels were dried down and subject to autoradiography.
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Figure 4C
TAFIIs are required for enhanced formation of TFIID-TFIIA complex formation. 1.5%
agarose gel shifts performed with 32 P-labeled ML probe with three Gal4 binding sites in
the presence of 100ng competitor dGdC. Topoisomerase I was titrated (0, 0.1, 0.3pl) into
binding reaction with 10ng TBP in the absence (lanes 1-3) and the presence (lanes 4-6) of
Gal4-VP16 (G), and with TBP and THIA in the absence (lanes 7-9) and presence (10-12)
of Gal4-VP16. Reactions were incubated for 1 hour at 300 C and then analyzed by
agarose EMSA. Gels were dried down and subject to autoradiography.
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Figure 5A
Activator increases the rate of formation of the THFIID-TFIIA complex in the presence of
topoisomerase I. 1.5% agarose gel shifts performed with 3 2P-labeled ML probe with
three Gal4 binding sites in the presence of 100ng competitor dGdC. Topoisomerase I,
THID and THIA were incubated with probe in the absence (lanes 1-5), and the presence
(lanes 6-10) of Gal4-VP16 for the indicated number of minutes at 300 C and then
analyzed by agarose EMSA. Gel was dried down and subject to autoradiography.
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Figure 5B
Rate of dissociation is not altered. 1.5% agarose gel shifts performed with 32 P-labeled
ML probe with three Gal4 binding sites in the presence of 100ng competitor dGdC.
Complexes were formed for 30 minutes at 300C in the absence (lanes 1-6) and the
presence of Gal4-VP16 (G) and then incubated in the presence of inhibitory amounts
(500ng) of dIdC for the times shown (in minutes) , at 300C. Binding reactions were then
analyzed by agarose EMSA. Gel were dried and subject to autoradiography.
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Figure 6
TFIIA is required for fast complex formation. 1.5% agarose gel shifts performed with
32P-labeled ML probe with three Gal4 binding sites in the presence of 100ng competitor
dGdC. TFIIA was titrated over three logs with TFIID (lanes 1-4), THID and
topoisomerase I (lanes 5-8), and TFIID, topoisomerase I, and Gal4-VP16 (G) (lanes 9-12)
for 20 minutes at 300C and then analyzed by agarose EMSA. Gels were dried down and
subject to autoradiography.
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Figure 7
Order-of-addition demonstrates the requirement for concomitant presence of THID,
TFIIA, activator and topoisomerase I for enhanced complex formation. 1.5% agarose gel
shifts performed with 32P-labeled ML probe with three Gal4 binding sites in the presence
of 100ng competitor dGdC. Factors indicated were incubated for 10 minutes at 300C
with probe. Second incubation, with factors indicated, for 5 minutes at 300 C preceded
analysis by agarose EMSA. Gel was dried down and subject to autoradiography.
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Figure 8
Catalytically inactive point mutant topoisomerase I potentiates activation with Gal4-
VP16 but does not support efficient elongation. ML transcript (180nt) was generated by
25ng supercoiled MLP basal control promoter. ML-3G transcript (390nt) was generated
by 25ng supercoiled MLP with three Gal4 binding sites fused upstream. Mutant
topoisomerase I was titrated (100, 200, 300, 400, 500ng) in the absence (lanes 1-6) and
the presence (lanes 7-12) of the activator Gal4-VP16. Transcription reactions were
analyzed, after purification, on 10% polyacrylamide gels with 8M urea, and subject to
autoradiography.
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Figure 9
Catalytically inactive point mutant topoisomerase I potentiates formation of the THFIID-
THIA complex in the presence of activator. 1.5% agarose gel shifts performed with 32P-
labeled ML probe with three Gal4 binding sites in the presence of 100ng competitor poly
dGdC. Mutant topoisomerase I was titrated (100, 200, 400ng) in the absence (lanes 1-4)
and the presence (lanes 5-8) of Gal4-VP16 and incubated for 20 minutes at 300 C prior to
analysis by agarose EMSA. Gel was dried down and subject to autoradiography.
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Figure 10 (following page)
DNAse I footprinting demonstrates recruitment of the TFIID-TFIIA complex to the
promoter by activator and coactivating topoisomerase I. Complexes were formed as in
EMSA reactions and then subject to DNAse I cleavage prior to analysis on 8% PAGE 8M
urea gels. Dried down gel was subject to autoradiography.
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Figure 11 (following page)
Camptothecin mediated cleavage of the ML-3G promoter region by topoisomerase I.
Complexes were formed under gel-shift conditions in the presence of 25gM
camptothecin. Probe was subsequently processed as described (Materials and Methods),
and analyzed by PAGE-urea. Dried down gel was subject to phosphorimaging.
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Figure 12.
Summary of DNAse I footprinting and camptothecin mediated cleavage data on the MLP.
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Figure 13.
Model of activated THFIID-THFIIA (blue-brown) complex with Gal4-VP16 (green) and
coactivating topoisomerase I (red) on the major late promoter (black).
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Materials and methods
Purification of topoisomerase I
Human DNA topoisomerase I was purified from HeLa cells as follows. Three
liters of cells at lx106 cells/ml were twice washed in 40 C PBS and lysed in 40ml lysis
buffer (50mM KC1, 10mM Tris-HCI pH 7.5, 2mM MgCl2 1% Triton X-100, 15mM
DTT, 0.15 mg/ml PMSF, 0.05 mg/ml aprotinin) by shaking. Nuclei were pelleted by
centrifugation and washed in 40ml lysis buffer without the Triton X-100. Nuclei were
repelleted by centrifugation and resuspended in 10 lysis buffer without the Triton X-100.
15ml nuclear extraction buffer (2M NaC1, 80mM Tris-HCI pH 7.5, 20% glycerol, 2mM
EDTA) was added and the lysis was mixed with a magnetic stir bar while 15ml of PEG
buffer (18% PEG 8000, IM NaC1, 10% glycerol) was added dropwise. Stirring was
continued for one hour at 40C. The lysate was cleared by centrifugation of 10kG for
10min. and the pellet was discarded. The supernatant was dialyzed overnight against 21
of potassium phosphate buffer (250mM KPO4, 10% glycerol, 1mM DTT, 1mM EDTA,
0.1mM PMSF). The dialysate was cleared by centrifugation and flowed over a 5ml bed
of phenyl superose (Pharmacia) equilibrated with 250mM KPO4 buffer pH 7.4 (with
1mM DTT, 1mM EDTA, 0.1mM PMSF) and onto a 5ml bed of phosphocellulose P11
(Whatman) equilibrated to 250mM KPO4 buffer. The phosphocellulose column was
washed with 250mM KPO4 buffer and eluted with 70mM KPO4 buffer. The eluate was
dialyzed against 100mM KPO4 buffer and then loaded on mono-S FPLC (Pharmacia)
column and developed with a linear gradient of KPO4 buffer (100-500mM). The
topoisomerase which eluted around 150mM KPO4 was dialyzed down to 100mM KPO4
and batch cleared with 2ml of mono-Q resin (Pharmacia) for one hour. Finally, the pure
topoisomerase I was dialyzed against 50% glycerol, 10mM Tris-HCI pH 7.5, 1mM DTT,
1 mM EDTA and stored at -200C.
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In Vitro Transcription
Transcription reagents and reactions were performed as described (Shykind et al.,
1995), and chapter II materials and methods).
EMSA and DNAse I footprinting
Agarose gel shifts and DNAse I footprinting reactions were performed as
described (Shykind et al., 1995) and chapter II materials and methods).
Camptothecin cleavage assay
Binding reactions were performed exactly as in footprint reaction and EMSA with
the addition of camptothecin (Sigma), (10mM in DMSO) to 25pM in the reactions from
time zero. After reaction at 300 C for 30 minutes, SDS was added to 0.2% and proteinase
K was added to a final concentration of 50ptg/ml. The reaction was then incubated at
37 0 C for 30 minutes and followed by extraction with phenol-chloroform-isoamyl alcohol
and ethanol-acetate precipitation. Finally, reactions were analyzed on 8% PAGE-urea gel
and subject to autoradiography.
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Chapter IV
Conclusions and Perspectives
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Summary of Data
Activation with HMG proteins
This work has attempted to identify and characterize factors involved in activation
of pol II transcription. Using a highly defined in vitro transcription system that was
active for basal transcription but unable to yield significant levels of activated
transcription, factors that restored the response to activators were characterized. This in
vitro system was also used as a functional assay wherein an activity was identified that
potentiated activation generally, without regard to activator class. This activity was
purified to homogeneity and determined to be the non-histone chromosomal protein
HMG-2. Subsequently, the highly related HMG-1 was shown to function similarly. The
80 amino acid HMG box, which is the minimal DNA binding and bending unit of HMG-
1 and 2, was also shown to coactivate stimulation, leading to the speculation that a
structural feature, critical to activated initiation was being stabilized by the HMG
coactivators. Surprisingly, the critical conformations or interactions that HMG-2
established on the promoter during activation were not accessible to the immunoglobulin
IgH I-promoter, a TATA containing, initiator lacking promoter. Activation was shown
to be dependent on TFIIA and first manifested its response at the TFIID-TFIIA binding
stage. Activation with HMG-2 was not associated with an increase in the amount of
TFIID-TFIIA complex as measured by EMSA and DNase I footprinting. This led to the
proposal that HMG-coactivated stimulation was the result of structural changes in the
TFIID-TFIIA complex that fostered subsequent steps of initiation.
Activation with DNA topoisomerase I
The chromosomal enzyme DNA topoisomerase I was analyzed in the defined in
vitro transcription reaction in the presence and absence of activators. Topoisomerase I
strongly potentiated stimulation with Gal4-VP16 in this system. Similar to HMG
coactivation, stimulation was first in evidence at the TFIID-TFIIA binding step.
161
Maximal activation required the concomitant presence of activator, coactivating
topoisomerase I, TFIID, and TFIIA. Unlike HMG coactivation, activation was associated
with a dramatic increase in the rate and extent of formation of the TFIID-TFIIA complex
as measured by EMSA and DNase I footprinting. Similar to HMG coactivation, this
enhanced complex formation was dependent on TAFIIs and TFIIA and the concomitant
presence of all four factors TFIID, TFIIA, activator and topoisomerase I. Neither the
enhanced complex formation nor the coactivation were dependent on the relaxing activity
of topoisomerase I, as shown by a catalytically inactive mutant. A camptothecin
mediated self-footprinting assay demonstrated the presence of topoisomerase I on the
promoter and its interaction with TFIID, dependent on the TAFIgs.
Architectural factor coactivators
The two mammalian coactivators studied in this thesis have many similarities.
Both are abundant proteins associated with chromatin, bind DNA non-specifically
(although topoisomerase I has some high affinity binding sites), and prefer irregular DNA
conformations such as crossovers and bent regions. Both appear to first function at the
TFIID-TFIIA binding step. The mammalian coactivator PC-4 also possess non-specific
DNA binding activity, and exerts its coactivation at the TFIID-TFIIA stage of initiation.
HMG-1/2 has been shown to form a complex with TBP on the promoter (Ge and Roeder,
1994), and topoisomerase I can coimmunoprecipitate with TFIID and far Western TBP
(Merino et al., 1993). Data presented here showed that topoisomerase I can interact with
TFIID on the promoter. Taken together, these data suggest that a critical event in
activation is occurring at the TFIID-TFIIA step and that this event requires the
participation not only of the activator but also of a structure inducing coactivator that
interacts both with TFIID and with the promoter DNA. Such a model of activation is
consistent with the formation of an enhanceosome The enhanceosome idea came from
the examination, in the Pol I system, of the xUBF-promoter complex (Bazett-Jones et al.,
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1994). xUBF is an HMG-box containing protein required for efficient activation.
Electron spectroscopic imaging (ESI) showed the xUBF dimer on the promoter to have
formed a 360 degree looped structure. The coactivator HMG-I(Y) was recently shown to
be a critical part of a large structure responsible for expression of the human interferon- 3
gene. This structure was formed through multiple and precise protein-protein and
protein-DNA interactions and hence was also termed an enhanceosome (Thanos and
Maniatis, 1995). HMG-I(Y) binds to the enhancer a several sites making contact both
with DNA and protein. These interactions resulted in the enhanced binding of both NF-
KB and ATF-2 in the enhancer. HMG-I(Y) binding was critical for the formation of this
multicomponent complex. The correct formation of an enhanceosome is proposed
require both correct bending and correct phasing of the bends. This idea has prokaryotic
antecedents (Tjian and Maniatis, 1994, and references therein). One of the first examples
of a eukaryotic enhancer dependent on precise structure for its function was the mouse T
cell receptor o-gene enhancer. This enhancer required several factors for its operation.
One of these factors, LEF-1, an HMG-box containing protein, only worked in the context
of its own enhancer. Further, mutations that altered its position in the enhancer abolished
activity (Giese et al., 1992; Giese et al., 1994). LEF-1 binds in the minor groove of DNA
and induces a sharp bend (Love et al., 1995). The ability of LEF-1 to induce structure in
the promoter is believed to be critical for enhancer formation. Thus enhanceosome
formation requires the participation of sequence-specific DNA binding proteins,
architectural factors, and protein-protein interactions.
In topoisomerase I mediated coactivation, there is evidence for several of the
features critical to enhanceosome formation. Both the activator, Gal4-VP 16, and TFIID
bind specifically to the promoter. There are protein-protein interactions between TFIID
and TFIIA, the Gal4-VP16 activation domain and TAF 40 and perhaps TAF 60, and
there is evidence that topoisomerase interacts both with TFIID and its TBP subunit both
off the promoter, and with TAFs on the promoter. There is evidence that topoisomerase
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binds to curved DNA and thus may stabilize bent structures. Topoisomerase I has been
shown by EM to bind to crossover DNA as well. The TBP subunit of TFIID binds and
bends the TATA box, and the Drosophila TAF 150 has been shown to mediate the
extensive downstream interactions on the initiator containing major late promoter.
Further TAFs 40 and 60 have been reported to contain the histone fold motif which is
involved in histone-histone and histone-DNA interactions (Kokubo et al., 1994) . These
TAFs may then mediate further promoter-DNA interactions in the complex. The overall
structure may be dramatically looped by the DNA bending activities of both TBP and
topoisomerase I. Further, the topoisomerase I bound upstream of the TATA box that is
stabilized by TFIID, may have to loop the DNA around in order to establish contact with
the TAFs. This proposal could be tested by knocking out the topoisomerase I binding
sites and assaying for the ability of topoisomerase I to coactivate. Additionally, high
resolution footprinting techniques could reveal subtle changes in the TFIID complex in
the putative enhanceosome. In HMG-1/2 mediated coactivation many of the same
interactions depicted above likely occur. The function of HMG-1/2 in this structure
however is not yet clear. Although HMG-1 has been shown to form a complex with
TBP, it is not known whether it will interact with TFIID on the promoter. Further,
coactivation by HMG-1/2 may require a functional initiator element as this coactivator
does not support activation on the immunoglobulin g-promoter. This may reflect an
HMG-1/2 binding site requirement or a TFIID conformational requirement, as TFIID
requires an initiator to make extended downstream contacts. HMG proteins will however
stabilize irregular or bent conformation of the promoter region.
The TFIID-TFIIA complex
Studies of both HMG proteins and topoisomerase I demonstrated that TFIID-
TFIIA complex formation was critical to activation. The result of this activated
formation upon the process could be qualitative, quantitative, or a mixture of both. There
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are models of activation depicting both extremes (see Introduction). It is possible that
activation in this in vitro system is tantamount to an increased TFIID-TFIIA complex
formation. Some of the EMSA data and the footprint data on topoisomerase I
coactivation would support this model in the absence of transcription data that shows that
a quantitative change does not fully explain activation. Further, the strict temporal
requirements of factor addition to the template, both for complex formation and for
maximal activation, suggest that a quantitative difference between activated and basal
TFIID-TFIIA complex is not an adequate explanation. The EMSA and footprint data on
HMG-1/2 coactivation support a model of pure qualitative change in the TFIID-TFIIA
complex upon activation. It is likely that both quantitative and qualitative differences are
occurring that distinguish the basal from the activated TFIID-TFIIA complexes and
participate in the positive modulation of the process. It will be of value to determine
whether the activated TFIID-TFIIA complex binds TFIIB, or other subsequently added
GTFs, with higher affinity than does the basal TFIID-TFIIA complex. Further, high
resolution footprinting should be used to determine the conformation of TFIID in both
complexes.
The Role of TFIIA
Although it has been shown to be non-essential to the basal transcription reaction,
the requirement for TFIIA in activation has been clearly established on a number of
promoters (see Introduction). In this thesis TFIIA was shown to be required in a highly
defined system with single coactivator driven activation. In vitro, TFIIA has been shown
to alter the TFIID footprint and to stabilize TBP and TFIID binding as measured by
EMSA and footprint. There is also evidence that TFIIA alters the conformation of TBP
on the promoter (Lee et al., 1992). Recently a yeast TBP mutant was described that
failed to support stimulation by acidic activators in vivo (Stargell and Struhl, 1995) This
mutant TBP retained its ability to bind to the VP16 activation domain, but lost its ability
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to bind to TFIIA. Fusion of the small subunit of TFIIA to the TBP restored its in vivo
function. Despite the demonstration of its critical role in activation, the function of
TFIIA in the process remains obscure. It could be that TFIIA allows recruitment of
TFIID by activator. This could occur via TFIIA-activator interaction as has been
described for the Zta activator (Ozer et al., 1994). EMSA with activator, TFIID, and
TFIIA show no recruitment in the absence of topoisomerase I (Chapter 3). It is also
possible that TFIIA allows the alteration of TFIID conformation in the presence of
activator (Lieberman and Berk, 1994), or activator and coactivator. Interestingly, TFIIA
has been shown to alter the core promoter selectivity of TFIID on the Drosophila tandem
Adh promoter (Hansen and Tjian, 1995). This specificity was dependent on the initiator
element and required TAF 150. Thus TFIIA can alter the specificity of TFIID promoter
recognition. Taken together, these data suggest that TFIIA may allow the massive TFIID
complex to adopt different conformations on the promoter by stabilizing alternate or
additional DNA contacts. Such conformations may be crucial to activated TFIID-TFIIA
complex formation. The inability of the immunoglobulin IgH g-promoter to support
HMG coactivation may be due to its lack of initiator element. This element, which is
protected by TFIID in DNase I footprinting assays (the extended footprint), may be
required for the proposed conformation of TFIID adopted in HMG coactivation. The
correlation of the extended footprint and the activated state has been made on the adeno
E4 promoter (Horikoshi et al., 1988; Horikoshi et al., 1988b).
Conclusion
In summary, the function of two soluble coactivators has been studied and the
initial stage of their action was determined to be the TFIID-TFIIA binding step. The
difference between the basal and activated TFIID-TFIIA complexes is likely a
combination of structural differences, and total amount of complex formed over time.
The qualitative changes upon activation are proposed to lead to an increased recruitment
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of GTFs subsequently added to the initiation complex. The challenge remains the
elucidation of the physical changes between the basal and activated TFIID-TFIIA
complexes that result in the functional differences between the basal and activated
reactions.
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Appendix A
Mechanism of basal repression by DNA topoisomerase I
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Abstract
Immobilized template transcription experiments were undertaken to determine the
mechanism of basal repression by DNA topoisomerase I. The ability of TFIID to commit
to the promoter equally well in the presence and absence of the repressor indicated that
the stage of repression was post TFIID commitment. Further analysis demonstrated that
topoisomerase I destabilized the TFIID-TFIIB complex on the promoter. Additionally,
topoisomerase I repression necessitated activities in addition to TFIIA for full
derepression of transcription, indicating that the derepressed initiation complex is altered
in function compared to naive complex.
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Introduction
DNA Topoisomerase I has been identified as a general repressor of Pol II
transcription in vitro (Kretzschmar et al., 1993; Merino et al., 1993). Merino observed
that topoisomerase I inhibited transcription from TATA containing promoters but a
TATA-less P3-DNA polymerase promoter was unaffected. Repression was reversible by
the addition of TFIIA, and preincubation of TBP with TFIIA resulted in a complex
resistant to topoisomerase I inhibition. Topoisomerase I coimmunoprecipitated with HA
tagged TFIID complex and remained bound to the complex up to 200mM KCl wash.
Further, topoisomerase I was shown to interact with TBP by far western assay.
Electrophoretic mobility shift assay with TBP demonstrated an antagonistic relationship
between the TBP-TFIIA complex and topoisomerase I. Although topoisomerase I could
inhibit the formation of the TBP-TFIIA complex, no corresponding TBP-topoisomerase I
complex was observed in EMSA. These data led to the conclusion that topoisomerase I
interferes with the ability of the TFIID complex to bind to TATA motif promoters and
thus inhibits basal transcription (Zawel and Reinberg, 1995).
Here, using an immobilized template transcription assay, evidence is presented
that topoisomerase I inhibits TFIID bound to the promoter. Repression of basal
transcription by topoisomerase I is demonstrated to occur by destabilization of the TFIID-
TFIIB-promoter complex. Further, topoisomerase I necessitates the requirement of
additional factors in order to support reinitiation of post TFIIA derepressed basal
transcription.
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Results
Experimental design
The mechanism of TFIIA derepression of topoisomerase I inhibition of the basal reaction
was examined on the Adeno major late promoter using epitope purified holoTFIID (Zhou
et al., 1992). The ability to immunoprecipitate the HA tagged TFIID in IM KCl
containing buffer insuring that topoisomerase I would be eluted from the complex and
washed away in the pre-elution IM KCI washes, was critical to the ability to start out
with a completely derepressed basal reaction (see Materials and Methods). To accurately
determine the stage of initiation repressed by topoisomerase I, an immobilized
transcription assay was set up wherein template was linked to streptavidin coated beads
(Dynal, Inc.) via a biotinylated dUTP incorporated by DNA Polymerase I Klenow
fragment (see Materials and Methods). Figure 1 shows the experimental design of the
transcriptions
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Figure 1
Experimental design of immoblized transcription assay. Biotinylated
transcription template is linked to magnet beads with covalently attac hed
streptav idin. First incubation factors commit to the template and th e
bound and non-specific proteins are washed away. Transcription commences
upon addition of the remaining necessary factors and nucleotides.
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Transcription reactions using the G-less cassette allow the visualization of reinitiation.
This is due to the fact that the polymerase stably stalls at the end of the cassette upon
transcribing up to the first guanidine, as no GTP is used in the reactions. If a second
polymerase is initiated, it will collide with the stalled first round pol, thirty nucleotides
from the end of the cassette, generating a shortened transcript. Thus subsequent
initiations will generate a ladder of transcripts each thirty nucleotides shorter then the
previous (Szentirmay and Sawadogo, 1991)..
Topoisomerase I inhibits holoTFIHD bound to the promoter
Figure 2 shows the results of commitment of TFIID under various salt conditions
and washing protocols in the absence and presence of topoisomerase I. TFIID could
commit to the major late promoter in up to 250mM but not 500mM or 1000mM KCI
(lanes 1-4). However, once committed, the complex was stable to a brief 1000mM KC1
wash (lane 7). If topoisomerase I was included in the commitment reaction with TFIID,
and washed in low (100mM) KC1, inhibition of transcription was observed upon addition
of remaining GTFs and nucleotides (lane 8). However, if the same binding reaction was
washed with 500mM or 1000mM KC1 containing buffer prior to addition of GTFs and
NTPs, the full level of transcription was restored (lanes 9 and 10). If a crude TFIIA
fraction (see Materials and Methods) was added to the topoisomerase I repressed complex
(lane 11) in the second incubation, basal transcription was restored but with a diminution
of the reinitiation (see Discussion and (Szentirmay and Sawadogo, 1991). A 1000mM
wash of the TFIID-topoisomerase I complex prior to addition of crude TFIIA fraction
restored full first round initiation and showed a slight increase in the second round
initiation (lane 12). Thus TFIID committed to the promoter as stably in the presence of
topoisomerase I as it did alone, and the repression of transcription by topoisomerase I was
reversible by TFIIA fraction or by high salt wash.
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TFIIA supports one round of initiation post derepression
To examine the factor requirements for derepression of topoisomerase I
inhibition, TFIIA preparations of different purities were used in the immobilized
transcription assay. As shown in Figure 3, purer TFIIA fractions generated less
reinitiation upon derepression. Lane 1 shows the high degree of reinitiation observed
when naive TFIID was committed to the template and GTFs are added in the second
incubation. Repression (lane 2), is derepressed to a lesser extent by the purer TFIIA
fractions (lanes 3-6) than by the less pure fraction (lanes 7) The apparent inability of the
purer TFIIA preparations to support full first round derepression may be spurious, as the
amount of counts in the first round initiate band likely represents first and some second
and third round initiations.
Reinitiation factor does not commit to the TFIID-TFIIA-topo I complex
The ability of crude TFIIA fraction to stimulate reinitiation in topoisomerase I
derepressed complexes was examined. Crude and pure TFIIA fractions were added either
in the first incubation where TFIID and topoisomerase I were committed, or were added
after the wash, in the second incubation. Figure 4 shows the results of this analysis. As
is typical, lane 1 showed the multiple rounds of initiation generated by committed naive
TFIID. Topoisomerase I inhibited this reaction (lane 2). As seen in lanes 3-6, if pure or
crude TFIIA fractions were added during the first incubation when TFIID and
topoisomerase I were committing to the promoter, first round initiation was restored, but
little reinitiation occurred. If the same fractions were added after this commitment, in the
second incubation, first round transcription was restored (lanes 7-9), but reinitiation was
only seen in the reaction containing crude TFIIA fraction (lane 9). Thus the reinitiation
activity could not commit to the early initiation complex and was lost in the wash step.
Thus it must function at a post TFIIA derepression step.
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Topoisomerase I destabilizes the TFIID-TFIIB complex
To determine the stage of initiation inhibited by topoisomerase I, the early
initiation complex TFIID-TFIIB was examined. This complex was suspected as a point
of interference in the basal reaction (see Discussion and Figure 6). As is shown in Figure
5. the TFIID-TFIIB complex formed fairly well on the immobilized template (compare
lanes 1 and 4). As might be expected, no reinitiation was observed when TFIID and
TFIIB were committed together as excess TFIIB was removed in the wash step and thus
became limiting in the reaction. The degree of transcription observed in the TFIID-TFIIB
committed reaction may be equal to that observed in the TFIID committed reaction (lane
1), for reasons discussed previously: the amount of counts in the first initiate band may be
due to contributions of first and subsequent initiations, depending on the stability of the
stalled polymerase II (see Discussion). When topoisomerase I was included in the first
incubation with TFIID and TFIIB, transcription was inhibited (lane 5). If TFIIA was
added to this reaction after the wash in the second incubation (lane 6), transcription was
not restored, indicating that the TFIIB was removed in the wash step. Transcription was
only restored if both TFIIA and TFIIB were added after the wash (lane 7), further
demonstrating the absence of TFIIB from the committed TFIID-topoisomerase I
complex.
Crude TFIID does not stably recruit TFIIB in the absence of TFIIA
Early experiments with the immobilized transcription assay were aimed at
determining the stage of TFIIA action in a crude in vitro transcription reaction strongly
dependent on TFIIA. Figure 6 shows such a reaction which contains second column
TFIID and GTFs and recombinant TFIIB. As can be seen comparing lanes 1 and 2, the
reaction was strongly dependent on TFIIA fraction. This dependence was not however
due to the inability of crude TFIID to bind as TFIIA fraction was able to derepress after
TFIID commitment (lane 3). Interestingly, this crude reaction behaved as did the defined
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in vitro reaction with topoisomerase I with respect to the ability of TFIIB to stably
associate with the TFIID complex. Lanes 7 shows the inability of TFIIA to be added
after the TFIIB-TFIID binding step, and in lane 6, its requirement at this stage. Thus
crude TFIID was unable to recruit TFIIB in the basal reaction as is the holoTFIID-
topoisomerase I complex.
Discussion
The mechanism of basal repression by topoisomerase I has been examined in a
highly defined in vitro transcription system. The repression was shown to occur on
template committed complexes and thus topoisomerase I does not interfere with the
ability of TFIID to bind to the TATA box. The repressed complex was derepressed with
high salt washes or with TFIIA fractions. Homogeneous preparations of cellular TFIIA
derepressed one round of transcription but poorly supported reinitiation. A crude TFIIA
preparation was observed to support both derepression and reinitiation. The activity that
restored multiple rounds of initiation was shown to act after initial derepression by
TFIIA. The stage of initiation inhibited by the repressor was demonstrated to be the
TFIID-TFIIB binding step.
The ability of topoisomerase I to form a repressed complex with TFIID on the
promoter is suggested by the retention of TFIID in a repressed state after the washing step
in the immobilized transcription protocol. While it is formally possible that
topoisomerase I alters the TFIID complex without binding to it, the demonstration of
Merino et al. that a TFIID-topoisomerase I complex can exist in solution off of the DNA
makes it appear likely that a similar complex exists on the promoter. The ability of high
KC1 washes to remove the repression further strengthens the idea of the existence of a
repressed, committed complex of TFIID and topoisomerase I.
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Derepression of the TFIID-topoisomerase I complex appears to be able to happen
in two forms: derepression of one round of transcription, and complete derepression
allowing multiple rounds of initiation. TFIIA allowed the former and TFIIA plus some
other not yet identified activity allows the later type of derepression. Interestingly, high
salt washes completely derepress the complex most likely by completely eluting the
topoisomerase I. These data suggest the topoisomerase I alters the function of the
initiation complex in the presence of TFIIA allowing it to send off one round of
transcription and then shut down. Such a mechanism may account for the reported
differential requirement of primary and subsequent initiations for elongation factors
(Szentirmay and Sawadogo, 1993). Sawadodgo's group observed that first round
initiations had no requirement for the elongation factor TFIIS. while the subsequent
rounds were strongly dependent on this activity for full length transcription. Thus
initiation and reinitiation have different factor requirements. It would be interesting to
determine whether the activity in the crude TFIIA fraction were TFIIS. The
chromatographic profiles of the two activities suggests that they are likely not the same.
Topoisomerase I has been suggested to remove the torsional strain caused by elongation
(Wang, 1985). It is possible that topoisomerase I is loaded onto the elongating
polymerase complex after association with the initiation complex. Such a loading may
require additional factors that would appear functionally as elongation factors. In the
absence of such loading factors, topoisomerase I may stall the reinitiation process. This
mechanism would be sensible, as torsional strain increases with each elongating
polymerase, thus topoisomerase I would be more highly required in secondary and
subsequent initiations.
In nuclear extracts TFIIB assembly into the initiation complex has been
demonstrated to be a rate limiting step during initiation (Lin and Green, 1991). This step
is facilitated by activators and a conformational change brought about in TFIIB by the
activator further stimulates initiation (Roberts and Green, 1994). It is possible that
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topoisomerase I is helping to mediate the slow TFIIB recruitment during initiation.
Suggestively, activator was shown to derepress topoisomerase I inhibition of initiation
(Merino et al., 1993). The ability of topoisomerase I to interact with the TFIID complex
likely lies in both its interactions with TBP and TAFs. It is possible that interactions
alters the configuration of the TFIID complex such that TFIIB does not bind. Upon
derepression by TFIIA, topoisomerase I may still alter the TFIID-TFIIB interaction such
that the low affinity TFIIB conformation is preserved and only one round of initiation
takes place. Activator and TFIIA may then restore high initiation rates in part by
completely derepressing the topoisomerase I-TFIID complex as part of the activation
process. Additionally, activator may aid in loading the topoisomerase I into the
elongation complex.
Topoisomerase I, an abundant, non-histone chromosomal protein has been
identified as a coactivator and a repressor of transcription (Kretzschmar et al., 1993;
Merino et al., 1993). It associates with the TFIID complex and prevents formation of the
TFIID-TFIIB complex and thus inhibits initiation. Upon derepression by TFIIA, it likely
stays associated with the initiation complex, and decreases the ability of that complex to
support reinitiation in the absence of yet unidentified factors.
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Figure 2
KCl titration during commitment and post-commitment.
Commitment of THID to the promoter under different KCl concentrations with
topoisomerase I. TFIID or TFIID plus topoisomerase I was committed in the presence of
increasing concentration ([KCl] in molarity) of KCI (lanes 1-4) or standard 0.1M KCI
(lanes 5-12) for one hour. Wash step in [KCI] as indicated, and second incubation in
0.060M KCl with remaining GTFs, one hour. Transcript (with first and second round
initiations labeled with arrows) generated by immobilized major late promoter driving
transcription from the 180nt G-less cassette. Crude TFIIA fraction added in second
incubation to reactions shown in lanes 11 and 12.
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Figure 3
Topoisomerase I mediated repression reversed by TFIIA.
TFIID or THID plus topoisomerase I was committed to the immobilized template for one
hour prior to wash. TFIIA fractions (IIA=homogeneous, #16=fifth column, pA=second
column) were added with the remaining GTFs and NTPs for one hour. Transcript (with
first, second, and third round initiations labeled with arrows) generated by immobilized
major late promoter driving transcription from the 180nt G-less cassette.
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Figure 4.
Reinitiation factor works post THFIID-TFIIA complex.
TFIID or TFIID plus topoisomerase I was committed to the immobilized template for one
hour prior to wash in the absence (lanes 1, 2, 7-9) or presence (lanes 3-6) of TFIIA
fractions (IIA=homogeneous TFIIA, pA=second column fraction). TFIIA fractions
(lanes 7-9) added with GTFs and NTPs in second incubation for one hour. Transcript
(with first, second, and third round initiations labeled with arrows) generated by
immobilized major late promoter driving transcription from the 180nt G-less cassette.
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Figure 5.
Topoisomerase I destabilizes the TFIID-TFIIA complex.
THID and indicated factors were committed to immobilized template for one hour prior
to wash (1st incubation). GTFs, NTPs, and indicated factors were incubated in the
second step for one hour. TFIIB was added in the first incubation in lanes 4-7, and added
in the second incubation in lanes 1-3, and 7. Transcript (with first, second, and third
round initiations labeled with arrows) generated by immobilized major late promoter
driving transcription from the 180nt G-less cassette.
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Figure 6.
TFIID fraction does not commit with THFIIB in absence of TFIIA.
Crude THID fraction or THID fraction plus TFIIB was committed to the immobilized
template in the presence (even numbered lanes) or absence (odd numbered lanes) of
second column TFIIA fraction. Crude GTFs and NTPs were added in the second
incubation along with THIA fraction (lanes 3, 4, 7, and 8) for one hour. Transcript (with
first, second round initiations labeled with arrows) generated by immobilized major late
promoter driving transcription from the 180nt G-less cassette.
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Materials and Methods
Immobilized templates
Adeno virus Major Late promoter driving a 190 nucleotide G-less cassette was cut out of
its 3kb pUC backbone with the appropriate restriction enzymes. The restriction reaction
was phenol-chloroform-isoamyl alcohol extracted and ethanol-acetate precipitated. The
fragments were next treated with Klenow fragment and dUTP-16-biotin (Boehringer-
Mannheim, GmBH). The Klenow reaction was run on a 1% agarose gel and the
biotinylated promoter fragment was isolated by glass milk procedure (Bio 101 Inc.)
Biotinylated fragments (500nt) were bound to M-280 streptavidin magnetic beads (Dynal,
Inc.) at a ratio of 20ng template per 1Ogl bead slurry (original suspension concentration).
Bead bound template was washed and stored in buffer A100-NP40 (20mM HEPES pH
7.9, 100mM KC1, 0.1% NP-40, ImM DTT, ImM EDTA pH 8.0, 20% glycerol) at 4oC.
Protein fractions
Crude TFIIA fraction ("pA")was a second column fraction (AB) from nuclear extract:
flow through of phosphocellulose at 40mM KCl and the 350mM bump off of DEAE.
Intermediate purity TFIIA was prepared as per Cortes et al., 1992 up to the ssDNA-
agarose step. Homogeneous TFIIA was prepared as described in Chapter two.
Topoisomerase I was obtained from Topogen, Inc and immediately dialyzed against
buffer A100-NP and stored at -700C. Crude transcription fractions were prepared as
described in (Buratowski and Sharp, 1990)
In vitro transcriptions
Transcriptions were carried out as described in Chapter two of this thesis except 5 1l of
bead-template slurry was added to reactions as template source. Reactions were mixed
by hand every twenty minutes during 300 C incubation.
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Appendix B
Topoisomerase I effect on linear templates
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Abstract
Topoisomerase I potentiates activation from linear and relaxed templates. However, it
differentially represses basal transcription dependent on transcript length when templates
are linearized. The effect is overcome by activator. Repression is independent of
promoter element type and is not significantly altered by TFIIA. Derepression is
activator non-specific. The topoisomerase-template ratio alters the effect, suggesting that
the degree of topoisomerase I loading on the template is critical to the phenomenon. The
mechanism of derepression is discussed.
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Introduction
In Chapter III of this thesis the activity of topoisomerase I with activator was
examined and found to result in an increase in the formation of the TFIID-TFIIA
complex. The coactivating activity was observed in a narrow window of titration
suggesting that cooperative binding was taking place. Camptothecin mediated cleavage
of the template suggested that topoisomerase was able to bind in the promoter region
where the initiation complex formed and that TFIID could recruit topoisomerase I to this
region dependent on its TAF subunits. In this appendix an unusual property of
topoisomerase I activity is examined. Upon titration of the enzyme, basal transcription
was boosted and then repressed, but with a different dose response dependent on the
length of transcript, when templates were linear. Additionally, activator was found to
prevent repressive effects dependent on TAFs, but not requiring TFIIA. This effect does
not require the catalytic activity of topoisomerase I as a catalytically inactive point
mutant of the protein functioned similarly. The phenomenon depends critically on the
template to topoisomerase I ratio and may result from a structure formed by the protein
during node binding. The ability of activator to derepress this inhibition may reflect the
formation of a superstructure within the initiation complex that prevents topoisomerase I
from forming crossovers that stochastically stall elongation complexes, or derepression
may result from the generation of more processive elongation complexes during
activation.
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Results
Topoisomerase I potentiates activation on supercoiled and linear templates as
shown in chapter III of this thesis. However, the effect on linears was somewhat
different: basal transcription was boosted from templates generating both long (390nt)
and short (180) and then repressed differentially, with long transcript inhibited before
short. This effect was examined on relaxed circular templates and linears with the
activator Gal4-VP16 to determine whether negative superhelical tension was required to
prevent this length dependent effect. As shown in Figure 1, template that was pre-relaxed
with topoisomerase I (lanes 1-6) behaved as did supercoiled template: both the long and
short transcripts effected similarly by the topoisomerase I at each point of titration. The
linear template (lanes 7-12) showed a differential effect, with transcription from the long
G-less cassette inhibited at lower topoisomerase I concentrations. In the presence of
activator, the relaxed circular template bearing three Gal4 sites showed activation as
topoisomerase I was added (lanes 4 and 5) and repression at the highest titration point
(lane 6). The linear template bearing the three Gal4 sites underwent derepression and
activation above basal (lane 11), and was repressed at the highest titration point (lane 12).
Interestingly, the circular templates, like the linear template generating long transcript,
were repressed at lower topoisomerase I levels than the linear template generating short
transcript.
To examine the specificity of the effect, a different promoter and activator were
tested from linearized template. Figure 2 shows that the cellular activator MLTF
similarly derepressed and activated transcription in the presence of topoisomerase I
(compare lanes 1-3 with 4-6). Further, the human heat shock promoter responded to
topoisomerase I as did the major late promoter: showing differential repression based on
transcript length in the basal reaction (lanes 7-9), and derepression and activation in
presence of activator (lanes 10-12).
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Relaxing activity not required
The catalytically inactive mutant topoisomerase I was used to test for the
requirement of relaxing activity in this effect. As seen in Figure 3, the mutant protein
behaved similarly to the wild type. Titration into transcription reactions in the absence of
activator (lanes 1-4) showed a basal boost from both templates and then repression from
the major late template generating the 390nt long G-less transcript. In the presence of
activator (Gal4-VP16), derepression and activation occurred (lanes 5-8). Thus the
catalytic activity of topoisomerase I was not a factor in this phenomenon. Suggestively,
both mutant and wild type protein are reported to bind to DNA with similar strength (see
discussion).
TAF requirement
To determine whether the derepression and activation of the long transcript by
activator required TAFs, recombinant human TBP was used to drive transcription from
the linearized major late promoters (Figure 4). Two concentrations of TBP were added to
transcription reactions and topoisomerase I was titrated in the absence (lanes 1-3 and 7-9)
and the presence of activator (lanes 4-6 and 10-12). At each TBP concentration,
topoisomerase I affected the two templates differentially, although the effect was not as
pronounced as was observed with TFIID. No activation or derepression was observed in
the presence of activator and a slight repression was seen from the Gal4 binding site
bearing templates (ML-3G). Thus TAFs are not required for the differential
topoisomerase I effect but are required for the derepression and activation observed in
this phenomenon.
Role of TFIIA
The repressive activity of topoisomerase I on basal transcription initiated from
TATA containing promoters is counteracted by TFIIA, highlighting this GTFs role in
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antirepression. TFIIA has additionally been shown to play a critical role in activation
both in vitro and in vivo. Here TFIIA was titrated in the basal reaction, and with
topoisomerase I in the presence and absence of activator, to examine the differential
topoisomerase I effect on linear templates. As seen in Figure 5, in the absence of TFIIA,
topoisomerase I repressed transcription from both templates, but more strongly from the
promoter generating the long transcript (lanes 1 and 2). Upon addition of activator (lane
3), some transcription was restored to the template bearing Gal4 sites, but this level fell
below the basal amount of transcription seen in lane 1. Thus TFIIA was not required for
modest levels of derepression by activator. Titration of TFIIA over three logs did not
alleviate the differential topoisomerase I effect. Interestingly, TFIIA was required for the
basal boost of topoisomerase I of the short transcript, and for activation above basal
levels. The basal effect is seen comparing 180nt transcript in lanes 1 and 2, to 10 and 11.
The effect on activation is seen comparing long transcript in lanes 2 and 3 to that in lanes
8 and 9. Thus derepression by activator did not require TFIIA, but activation above
basal, as well as the boost to basal transcription, did require TFIIA
Length effect
The effect of topoisomerase I on transcription of different length G-less cassettes
from linear templates was examined in Figure 6. Major late promoters with and without
Gal4 binding sites were tested in basal transcription. Topoisomerase I was titrated into
the reactions such that the template to topoisomerase I ratio was the same for each
template at equal titration points. Long transcripts showed a basal boost and then
repression below basal (no topoisomerase I added) levels from a major late containing
template with three Gal4 sites (lanes 1-3) and the same promoter without such sites. If
the promoter used in lanes 4-6 was driving transcription from a shorter (180nt) G-less
cassette (lanes 7-9), topoisomerase I had a less repressive effect at the top of the titration
range (lane 9). When the same promoter used in lanes 1-3 was used to drive transcription
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from a 70nt G-less cassette, the titration of topoisomerase I at the same protein-template
ratios yielded increased basal transcription even at the top of the titration range (lanes 10-
12). Length dependent repression of transcription by topoisomerase I did not generate
strong stops of transcription. The different length G-less cassettes used in each template
(180 and 70) were derived form truncations of the 390nt cassette.
Effect of different template-topoisomerase I ratios
The repressive effects of topoisomerase I and the effects of activator in this
reaction critically depended on the ratio of topoisomerase I to template. Figure 7
demonstrates that threefold changes in template concentration, at the same topoisomerase
I and GTF level, result in dramatically different outcomes for basal and activated
reactions. At the standard (lX) level of linearized template (25ng for each), as shown
previously, topoisomerase I boosts transcription of the 180nt transcript and inhibits the
390nt message (lane 5). The addition of activator generates activated levels of
transcription, much above basal. If the template concentration is dropped threefold (lanes
1-3), topoisomerase I inhibits both templates (lane 2), and activator derepresses the Gal4
binding site bearing promoter to sub-basal levels (lane 3). If the template concentration
is raised threefold, topoisomerase I boosts both long and short transcript (lane 8), and
activator stimulates above basal (lane 9).
Discussion
The effect of topoisomerase I on transcription from linear templates was
examined. Basal levels of transcription are boosted and then repressed as topoisomerase I
is titrated into in vitro reactions. However, all other factors equal, repression occurs at a
much lower topoisomerase I concentration when long transcript is being generated than
when a short transcript is transcribed. This repression appears general for different
promoters and is reversed by activator, which derepresses in the absence of TFIIA and
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activates transcription above basal levels in its presence. This differential effect does not
occur on negatively supercoiled nor relaxed circular templates. Further, the catalytic
activity of the enzyme is not required suggesting that binding of the protein to the
promoter effects the repression.
Preferential repression of long transcripts by topoisomerase I is not occurring by
the site specific binding of the protein to a high affinity site in the G-less region. Such an
event would generate a strong stop. Repression of the 390nt transcript shows no such
strong stops. This repression is not occurring by an inhibition of initiation, as identical
promoters linked to G-less cassettes of different lengths show different dose responses to
topoisomerase I. However, it is formally possible that topoisomerase I acts during
initiation, in a template topology dependent manner, to generate elongation complexes
possessing poor processivity. It is also formally possible that topoisomerase I is binding
to a site in the G-less cassette after +200 and affecting initiation, but such an event would
not explain the gradient of repression seen with increasing transcript length.
Topoisomerase I does have nonspecific DNA binding activity and may be binding along
the length of the G-less region and causing nonspecific and random termination of
elongation. Such random binding and interference would effectively generate the
elongation effect seen here. Random arrest of elongation would generate a ladder of
truncated transcripts of "full length-N" nucleotides that would spread out down the length
of the lane and become to faint to detect. This random repression could come from non-
specific DNA binding or from the ability of topoisomerase I to bind at nodes where one
strand of DNA crosses over another (Zechiedrich and Osheroff, 1990). The reported
lower affinity of topoisomerase I to linear versus supercoiled DNA may also account for
the topology difference of inhibition. The lower affinity for linear DNA may mean that
topoisomerase I is binding sparsely along the linear template, thus generating infrequent
and random stops to elongation. Tight binding to supercoiled template may inhibit
elongation completely without generating a length dependent effect.
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Given such a nonspecific mechanism of elongation arrest, it is not surprising that
the effect is promoter independent and not significantly altered by GTF titration. It is
striking however that activator can completely reverse the block. This suggest that either
activator is 1) clearing the template of the protein, 2) forming an initiation complex that
excludes it, or is 3) generating elongation complexes that have greater processivity.
Although activators have been shown to derepress transcription from chromatinized
templates, those derepressive effects were likely acting at the stage of initiation
(Workman et al., 1990). It is unlikely that activator is clearing the template of
topoisomerase I on its own as the ability to derepress is dependent on the presence of
TAFs. It is possible that an activated initiation complex structure forms that excludes the
topoisomerase I from the template. This exclusion would have to extend farther away
from +1 than has been reported for the complete complex (Buratowski et al., 1989), to
effectively counteract the repression. Activators have been reported to increase
elongation (Yankulov et al., 1994). This effect is proposed to occur through an increase
is the processivity of the elongation complexes, as opposed to template clearance
phenomena. The ability of activators to derepress and activate transcription on linear
templates in the presence of topoisomerase I may result from an increase in the
processivity of the elongation complexes. It is also possible that the increased initiations
may simply knock the topoisomerase I off the template, allowing subsequent elongation
complexes full-length elongation.
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Figure 1.
Transcriptional effects of topoisomerase I on relaxed circular and linear templates.
Linear major late promoter with three Gal4 sites driving transcription off of the 390nt G-
less cassette (ML-3G), and linear major late promoter alone driving transcription off of
the 180nt G-less cassette (ML) were tested in the absence of activator (-), and the
presence of the activator Gal4-VP16 (G). Topoisomerase I was titrated (0, 100, 200) into
the reactions.
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Figure 2.
Transcriptional effect of topoisomerase I on different promoters and different activators.
Linear major late with five MLTF binding sites (ML-5M) and linear human heat shock
promoter with three Gal4 binding sites (HSP-3G) each driving transcription off of the
390nt G-less cassette were tested. Major late promoter alone was included as linear basal
control. Purified cellular MLTF (M) was added in lanes 4-6, and Gal4-VP16 (G) was
added in lanes 10-12. Topoisomerase I titrated at 0, 100, 200.
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Figure 3.
Mutant topoisomerase differentially represses elongation. Linear major late promoter
with three Gal4 sites driving transcription off of the 390nt G-less cassette (ML-3G), and
linear major late promoter alone driving transcription off of the 180nt G-less cassette
(ML) were tested in the absence of activator (-), and the presence of the activator Gal4-
VP16 (G). Mutant topoisomerase was titrated at 0, 100, 200, 300ng into reactions.
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Derepression requires TAFs. Linear major late promoter with three Gal4 sites driving
transcription off of the 390nt G-less cassette (ML-3G), and linear major late promoter
alone driving transcription off of the 180nt G-less cassette (ML) were tested in the
absence of activator (-), and the presence of the activator Gal4-VP16 (G). Recombinant
human TBP was used in amounts shown. Topoisomerase I was titrated into reactions at
0, 100, 200ng.
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Figure 5
Titration of TFIIA. Linear major late promoter with three Gal4 sites driving transcription
off of the 390nt G-less cassette (ML-3G), and linear major late promoter alone driving
transcription off of the 180nt G-less cassette (ML) were tested in the absence of activator
(-), in the presence of 100ng topoisomerase I (T), and in the presence of both
topoisomerase I and the activator Gal4-VP16 (GT). TFIIA was titrated over three logs of
dilution.
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Figure 6
Transcript length effect on linear templates. Linear major late promoter with three Gal4
sites driving transcription off of the 390nt G-less cassette (lanes 1-3) and 70nt G-less
cassette (lanes 10-12), major late promoter alone driving transcription off of the 390nt G-
less cassette (lanes 4-6) and 180nt G-less cassette (lanes 7-9) were tested in transcription
at 50ng each. Topoisomerase I was titrated into reactions at 0, 100, and 200ng.
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Figure 7
Template-protein ratio alters topoisomerase I effect. Linear major late promoter with
three Gal4 sites driving transcription off of the 390nt G-less cassette (ML-3G), and linear
major late promoter alone driving transcription off of the 180nt G-less cassette (ML)
were tested in the absence, in the presence of 100ng topoisomerase I, and in the presence
of both topoisomerase I and the activator Gal4-VP16 (G). 25ng of each template were
used in lanes 4-6 (IX), 75ng of each in lanes 7-9 (3X), and 8.3ng of each in lanes 1-3
(0.33X)
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Materials and Methods
Transcription factors
All factors and transcription conditions are as described in chapter III. MLTF was
purified as described in chapter II. Topoisomerase I was purified as in chapter III.
Transcription templates
Major late templates used here are as described in chapter II except the ML-3G driving a
70nt G-less cassette which was derived by P.C.R. generated truncation of the 390nt G-
less sequence at +70 by J. Kim, Sharp lab.
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Appendix C
Coactivator-coactivator interaction
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Abstract
The defined mammalian coactivators PC-4, HMG-2, and topoisomerase I were titrated
together into transcription reactions to examine whether additive or synergistic activation
would occur. Mutual titration of any of these coactivators led to repression of both basal
and activated transcription.
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Introduction
The inability of the basal reaction to support activation has led to the
identification and analysis of additional factors that potentiate stimulation by site-specific
activators (see Introduction). The contribution of both activation and derepression of
transcription have been proposed to account for the dramatic levels of gene induction
observed in vivo (Meisterernst et al., 1991b). Synergy in activation is likely due to
multiple activator-GTF interactions (Chi et al., 1995). Coactivators, which functionally
link the basal machine with the site-specific activators that potentiate the reaction, likely
mediate the multiple contacts required for synergistic activation; as is the reported case
with TAF coactivators (Sauer et al., 1995).
Topoisomerase I, PC-4, and HMG-2 are general coactivators of mammalian
transcription (Kretzschmar et al., 1993; Merino et al., 1993; Ge and Roeder, 1994b;
Kretzschmar et al., 1994; Shykind et al., 1995); each has been shown to potentiate
activation from several different activators. Here they are tested for the ability to
augment activation by mutual titrations in the defined transcription system. Despite the
ability of each to potentiate activation on their own, together, in all combinations tested,
they inhibit activated and basal transcription.
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Results
Requirement for coactivators
Activation in the defined transcription system used in these studies requires
soluble coactivators (Shykind et al., 1995). To assess the baseline activation in this
system in the absence of all but the TAF coactivators in the holoTFIID complex (Zhou et
al., 1992), the synthetic activator Gal4-VPl6 was titrated over three logs in the absence
and presence of the coactivator HMG-2 (Figure 1). As Gal4-VPl6 was titrated into the
transcription reaction on its own, a slight increase was observed in the level of transcript
generated from the template bearing three Gal4 binding sites (ML-3G, lanes 1-4). This
level of activation was similar to that seen using TBP. In the presence of HMG-2,
titration of activator generated significant levels of activation. Additionally, the basal
level of transcription was slightly boosted by the coactivator (compare lanes 1 and 5).
Thus this system is likely devoid of significant levels of contaminating coactivators.
Further, the TAFs alone did not support significant levels of activation in this system.
Titration of HMG-2 with PC-4
The effect of multiple coactivators on activation was examined with HMG-2 and
PC-4 (Figure 2). In the absence of PC-4 and activator, HMG-2 titration resulted in a
slight boost to basal transcription (lanes 1-3). However, in the presence of subsaturating
amounts of PC-4, titration of HMG-2 resulted in an inhibition of basal transcription
(lanes 4-6). The presence of activator generated a characteristic level of activation upon
HMG-2 titration (lanes 7-9). Activator and PC-4 alone (lane 10) gave some stimulation
of transcription. Titration of HMG-2 in the presence of activator and PC-4 showed a
repression of both activated and basal levels (lanes 11-12).
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Titration of topoisomerase I with PC-4
Figure 3 shows the effect of titration of topoisomerase I with PC-4. In the
absence of activator (lanes 1-4), topoisomerase I titration with PC-4 resulted in an
inhibition of basal transcription. In the presence of activator (lanes 5-8) PC-4 potentiated
stimulation (lane 6). Addition of the lowest level of topoisomerase I had not effect on the
reaction (lane 7), but its further addition caused inhibition of all transcription (lane 8).
The level of activated transcription was not altered by addition of both coactivators, but
the net activation was increased when the basal transcription in lane 2 is compared to the
activated level in lane 6 versus the comparison of lanes 3 to 7, where both coactivators
were present. Thus PC-4 and topoisomerase I do not cooperated in coactivating
stimulation, but can increase net activation by a combination of repression of basal and a
potentiation of activated levels.
Titration of topoisomerase I with HMG-2
The last combination of coactivators tested together were HMG-2 and
topoisomerase I. On supercoiled templates (Figure 5), topoisomerase I boosted and then
repressed transcription (lanes 11-13). Activator generated strong stimulation when
topoisomerase I was titrated into the reaction (lanes 14-15), and then repression at the top
of the range (lane 16). In the presence of HMG-2, the same titration range of
topoisomerase I inhibited transcription completely (lanes 1-4). Activator derepressed the
inhibition to basal levels (lane 7), and further titration of topoisomerase I completely
inhibited transcription (lanes 8-9). Finally, topoisomerase I was tested with HMG-2 on
linear templates, where similar effects were observed (Figure 6). In the absence of
activator (lanes 1-3), characteristic repression based on transcript length was seen (see
Appendix B). Activator derepressed the reaction (lanes 4-6). Addition of HMG-2 caused
full repression at all levels of topoisomerase I addition in the absence (lanes 7-9) and the
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presence of activator (lanes 10-12). Thus no additive or cooperative effects on activation
were generated by addition of both HMG-2 and topoisomerase I coactivators.
Discussion
The ability of the defined coactivators HMG-2, PC-4, and topoisomerase I to
mutually potentiate activation in an in vitro reaction highly dependent on the soluble
coactivators was examined. Whereas each coactivator was able to augment stimulation
on its own, no additive nor cooperative effects were observed on activation. The net level
of activation could, however, be slightly raised by a preferential repression of the basal
reaction.
Activation in vivo reaches induced to uninduced ratios far greater then those
attained in vitro. This discrepancy may be due to the artifactually high uninduced or
basal level of transcription. The naked DNA templates used in vitro allow initiation in
the absence of activators. It has been proposed that chromatinized template prevents such
basal initiation in vitro (reviewed in Paranjape et al., 1994). Perhaps the ratios of
activated to basal transcription on naked DNA in vitro should not be expected to reach in
vivo levels. None-the-less, the examination of activation in vitro has attempted to
achieve such high stimulation levels. These levels have been proposed to be mediated by
the combination of positive and negative cofactors (Meisterernst and Roeder, 1991;
Meisterernst et al., 1991b). This study demonstrates that the combination of previously
identified positively acting cofactors of stimulation does not yield additive of
multiplicative levels of activation. This is in contrast to the TAF coactivators that have
been shown to mediate activation singly, and synergy when multiple TAFs are present in
the TFIID complex (Sauer et al., 1995).
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The factors used in this study are all present in nuclei of mammalian cells. Their
inability to cooperate may suggest that they are not present together in all transcription
reactions. It is possible that different coactivators are localized to different promoters or
chromosomal regions, thus avoiding antagonism. Alternatively, the highly purified in
vitro reaction may be missing factors that allow the functional interaction between these
coactivators. It is also possible that the presence of just three Gal4-VP 16 activators is not
sufficient to necessitate multiple coactivators. Differences between the activity of one or
a few activators have been demonstrated in vitro (Choy and Green, 1993; Chi et al.,
1995). Interestingly, each of the coactivators used in this study have been shown to exert
their activity at the TFIID-TFIIA stage of initiation during activation (Kaiser et al., 1995;
Shykind et al., 1995, and Chapter III). Thus they may be antagonizing critical
interactions at this stage unique to the mechanism of each. Alternatively, they may all
have the same mechanism and therefore addition of any two, may simply be tantamount
to over-addition of one, and cause repression.
The data presented here may also explain the reported identification of HMG-2
and 1 as repressors (Ge and Roeder, 1994a; Stelzer et al., 1994), as the titration of HMG-
2 into the in vitro systems used by these authors would have caused repression if either
topoisomerase I or PC-4 were present. The ability of topoisomerase I to associate tightly
with TFIID could for such a contamination (Merino et al., 1993).
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Figure 1.
Requirement for soluble coactivators.
Gal4-VP16 was titrated over three logs (0.5, 5, 50ng) in the absence lanes 1-4 and the
presence of 200ng recombinant human HMG-2 lanes 5-8. ML-3G transcript (390nt) was
generated by 25ng of supercoiled major late promoter (MLP) with three Gal4 binding
sites fused upstream. ML basal control transcript (180nt) was generated by 25ng of
supercoiled MLP.
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Figure 2.
Titration of HMG-2 with PC-4. Recombinant human HMG-2 was titrated (0, 200,
400ng) in the absence and presence of 150ng recombinant human PC-4, with and without
Gal4-VP16. ML-3G transcript (390nt) was generated by 25ng of supercoiled major late
promoter (MLP) with three Gal4 binding sites fused upstream. ML basal control
transcript (180nt) was generated by 25ng of supercoiled MLP.
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Figure 3.
Titration of topoisomerase I with PC-4. Purified human topoisomerase I was titrated (0,
100, 200ng) with PC-4 in the absence (lanes 1-4) and the presence (lanes 5-8) of Gal4-
VP16 (G). ML-3G transcript (390nt) was generated by 25ng of supercoiled major late
promoter (MLP) with three Gal4 binding sites fused upstream. ML basal control
transcript (180nt) was generated by 25ng of supercoiled MLP.
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Figure 4.
Titration of topoisomerase I with HMG-2. Purified human topoisomerase I was titrated
(0, 100, 200, 300ng) into transcription reactions with HMG-2 in the absence (lanes 1-5,
11-13) and presence (lanes 6-10, and 14-16) of Gal4-VP16 (G). ML-3G transcript
(390nt) was generated by 25ng of supercoiled major late promoter (MLP) with three Gal4
binding sites fused upstream. ML basal control transcript (180nt) was generated by 25ng
of supercoiled MLP.
217
l 9 p-I
HMG-2
_m mw
- G - G
Im II II
Topo I:
ML3G--
-A-
9
linear
ML-2 
1 2 3
9
4 5 6 7 9 10 11 12
Figure 5.
Titration of topoisomerase I with HMG-2 on linear templates. Purified human
topoisomerase I was titrated (0, 100, 200ng) into transcription reactions with and without
HMG-2, in the absence (lanes 1-3, and 7-9) and presence (lanes 4-6 and 10-12) of Gal4-
VP16 (G). ML-3G transcript (390nt) was generated by 25ng of linear major late
promoter (MLP) with three Gal4 binding sites fused upstream. ML basal control
transcript (180nt) was generated by 25ng of linear MLP.
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Materials and Methods
Transcription reactions
General transcription factors, activator and HMG-2 were prepared as described in
chapter II. Purified human DNA topoisomerase I was prepared as described in chapter
III. Recombinant human PC-4 was a gift of J. Parvin (Harvard Medical School, Boston,
MA). Transcription templates used were described in chapter II.
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